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SUMMARY 
 Streptococcus agalactiae or group B Streptococcus (GBS) is a Gram-
positive bacterium asymptomatically colonizing 15-35% of women in the 
gastrointestinal and urogenital tracts. During delivery, neonates born to mothers 
who carry GBS can be infected themselves and develop severe diseases such as 
sepsis, pneumonia and meningitis. Pre-partum screenings and prophylactic 
treatment with antibiotics have reduced the incidence of neonatal GBS disease to 
0.04% in USA. But still, in the western world, S. agalactiae represents the major 
cause of bacterial meningitis in newborns and half of the infected suffer long-term 
neurodevelopmental defects. Moreover, GBS has also emerged as a pathogen in 
other patient populations such as the elderly, pregnant women, diabetics and 
individuals who are immunocompromised. Vaccines based on the capsule 
polysaccharide (CPS) of this pathogen are currently under development.  
 The CPS is the main virulence factor of GBS, preventing complement 
deposition and opsonophagocytosis. The production of a CPS is ubiquitous in 
bacteria, and the Wzy pathway constitutes one of the prototypical mechanisms to 
produce these structures. This pathway has been characterized in detail in S. 
pneumoniae. Briefly, the repeating units of sugars composing the CPS are 
synthesized inside the cell by a group of glycosyltransferases. The repeating units 
are then flipped outside the membrane and incorporated into the growing 
polysaccharide chain by a polymerase. Lastly, the polysaccharide is attached to 
the cell wall peptidoglycan to create the CPS layer surrounding the bacterium. All 
the enzymes involved in this process are encoded in a single operon. 
 The aim of this work is to investigate the role of the CpsABCD proteins 
encoded in the cps operon of GBS. These proteins are highly conserved in all 
GBS serotypes, as well as in some other related bacteria, but they are not involved 
in the synthesis of the basic repeating units of sugars. CpsA is reported to be a 
transcriptional regulator and/or an enzyme attaching the CPS to the cell wall. 
CpsBCD homologous proteins in S. pneumoniae constitute a putative 
phosphoregulatory system, but their role in GBS capsule biosynthesis is unclear. 
To investigate the role of these proteins we developed twelve knockout and 
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functional GBS mutant strains and we examined them for CPS quantity, size, and 
attachment to the cell surface, as well as CpsD phosphorylation. Moreover, we 
used a bacterial two hybrid assay to investigate interdependencies between these 
proteins.  
 We observed that in GBS CpsB, C and D constitute a phosphoregulatory 
system where the CpsD autokinase phosphorylates its C-terminal tyrosines in a 
CpsC-dependent manner. These Tyr residues are also the target of the cognate 
CpsB phosphatase. Analysis of cps operon transcription by qRT-PCR on the 
mutant strains suggested that CpsABCD are not involved in transcriptional 
regulation of this operon. Furthermore, all the mutant strains retained the 
capability to produce a CPS, confirming that these proteins are not involved in the 
synthesis of polysaccharides, however, differences in CPS length and attachment 
to the cell wall were observed. In particular, we observed that the CpsC 
extracellular domain appeared necessary for the production of high molecular 
weight polysaccharides and that the LytR domain of CpsA is required for the 
attachment of the CPS to the bacterial cell surface. Protein-protein interactions 
between CpsD and CpsC and between CpsA and CpsC were observed.  
 These results allowed us to propose tentative roles for the proteins and 
their interdependencies. We propose a model where these proteins are fine-tuning 
the steps terminating the CPS biosynthesis, i.e. the balance between 
polymerization and attachment to the cell wall. In said model, CpsA competes 
with the CPS polymerase and attaches the CPS to the cell wall. This interplay 
depends on the cyclic phosphorylation of the CpsCD complex which modulates 
the activity of CpsA balancing the two competing activities. 
 Ultimately, to investigate how differences in CPS length, amount and 
localization impact on S. agalactiae ability to interact with cells, an in vitro 
adhesion-invasion assay, using lung epithelial cells have been tested. Our results 
showed that strains with CPS length different from the wild type were defective in 
associations to cells. Moreover, strains lacking the capsule or producing very little 
CPS were more efficient in invading cells irrespective of the CPS length. 
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RIASSUNTO 
 Streptococcus agalactiae, anche detto streptococco gruppo B (GBS), è un 
batterio Gram-positivo comunemente identificato come colonizzatore 
asintomatico del tratto gastrointestinale e urogenitale nel 15-35% delle donne. 
Durante il parto, GBS può essere trasmesso dalla madre colonizzata al neonato, il 
quale può sviluppare sepsi, polmoniti o meningiti. La diffusione di screening e 
trattamenti profilattici pre-parto ha significativamente ridotto l’incidenza delle 
malattie neonatali causate da GBS. Negli Stati Uniti, ad esempio, l’incidenza 
media di queste infezioni è dello 0.04%. Nel mondo occidentale, tuttavia, S. 
agalactiae rappresenta ancora la prima causa di meningiti batteriche nei neonati e 
la metà degli infetti soffre di difetti nello sviluppo neurologico a lungo termine. 
Patologie causate da GBS sono riscontrate anche in altri tipi di pazienti, quali gli 
anziani, le donne gravide, i diabetici e gli immunodepressi. Alcuni vaccini contro 
GBS sono attualmente in fase di sviluppo e sono basati sul polisaccaride capsulare 
(CPS) di S. agalactiae. 
 Il CPS è il maggior fattore di virulenza di GBS ed è in grado di inibire la 
deposizione del complemento sulla superficie del patogeno e l’opsonofagocitosi. 
La presenza di una capsula polisaccaridica che riveste la superficie batterica è una 
caratteristica comune a molti batteri e il pathway Wzy e uno dei tipici meccanismi 
usati per produrre i polisaccaridi che compongono questa struttura. Questo 
processo è stato descritto in dettaglio per S. pneumoniae. La produzione del CPS 
inizia all’interno della cellula con la sintesi delle unità saccaridiche da parte di una 
serie di glicosiltrasferasi. Successivamente le unità sono trasferite sul lato esterno 
della membrana batterica dove una polimerasi incorpora le unità ripetute al 
polisaccaride nascente. Il polisaccaride viene infine attaccato al peptidoglicano 
della parete cellulare e crea lo strato della capsula. Tutti i geni che codificano gli 
enzimi responsabili di questo processo si trovano in un unico operone.  
 Lo scopo di questa tesi è di investigare il ruolo delle proteine CpsABCD 
codificate dall’operone cps. Queste proteine sono conservate in tutti i sierotipi di 
GBS e in altri batteri, ma non sono direttamente coinvolte nella biosintesi delle 
unità saccaridiche che compongono il CPS. In letteratura, CpsA è descritto come 
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un regolatore trascrizionale o un enzima che attacca il CPS alla parete cellulare. 
Le proteine omologhe di CpsBCD di S. pneumoniae compongono un sistema di 
fosforegolazione la cui funzione nell’ambito della biosintesi del CPS non è stata 
chiarita. Per studiare il ruolo di CpsABCD in GBS abbiamo sviluppato dodici 
mutanti in cui i geni cpsABCD sono stati deleti o mutati. Per ognuno di questi 
mutanti sono stati caratterizzati la quantità, la dimensione e la localizzazione 
cellulare del CPS prodotto, e lo stato di fosforilazione di CpsD. Inoltre mediante 
l’uso del bacterial two hybrid assay sono state analizzate le interazioni tra alcune 
di queste proteine. 
 I risultati ottenuti hanno dimostrato che, anche in GBS, CpsB, C e D 
compongono un sistema di fosforegolazione in cui CpsD è l’autochinasi e CpsB è 
la fosfatasi. CpsD fosforila le tirosine che si trovano al suo C-terminale e la sua 
attività è dipendente dalla presenza della coda C-terminale di CpsC. Le tirosine di 
CpsD sono a loro volta defosforilate da CpsB. La trascrizione dell’operone cps è 
stata analizzata mediante qRT-PCR in tutti i mutanti e i risultati hanno mostrato 
che le proteine CpsABCD non sono coinvolte nella regolazione trascrizionale 
dell’operone. Inoltre, l’osservazione che i mutanti mantengono la capacità di 
produrre il CPS, conferma che queste proteine non partecipano alla sintesi del 
polisaccaride. Tuttavia, per alcuni mutanti sono state osservate differenze nella 
lunghezza del CPS e nella sua localizzazione. I dati ottenuti suggeriscono che il 
dominio extracellulare di CpsC è necessario per la produzione di polisaccaridi ad 
alto peso molecolare e il dominio LytR di CpsA è responsabile del trasferimento 
del CPS alla parete cellulare. Infine, lo studio delle interazioni tra proteine ha 
dimostrato che CpsC interagisce con CpsD e CpsA.  
 Queste evidenze sperimentali hanno permesso di suggerire delle possibili 
funzioni per CpsABCD. Queste proteine sono principalmente coinvolte nella 
regolazione dei due processi che terminano la biosintesi del CPS: la 
polimerizzazione e il trasferimento del polisaccaride alla parete cellulare. Nel 
modello che proponiamo, l’elongazione del CPS da parte della polimerasi viene 
interrotta dall’azione di CpsA che trasferisce il polisaccaride neosintetizzato alla 
parete cellulare. L’azione di CpsA viene modulata dallo stato di fosforilazione del 
complesso CpsCD che è quindi responsabile del bilanciamento dei due processi di 
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elongazione e trasferimento del CPS alla parete cellulare. 
 Infine, abbiamo studiato l’impatto delle differenze fenotipiche del CPS 
sulla capacità di GBS di interagire con le cellule umane. A questo scopo è stato 
impiegato un saggio di adesione-invasione in vitro usando cellule epiteliali 
polmonari e alcuni dei mutanti sviluppati. I risultati ottenuti hanno mostrato che i 
mutanti aventi un CPS di lunghezza diversa dal ceppo wild type presentano difetti 
di adesione alle cellule. Inoltre i ceppi privi di CPS o aventi una bassa quantità di 
CPS sono in grado di invadere le cellule più efficacemente, indipendentemente 
dalla lunghezza del polisaccaride prodotto.  
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INTRODUCTION 
Brief history of Streptococcus agalactiae 
 Streptococcus agalactiae is a Gram-positive bacterium also known as 
group B streptococcus (GBS) on the basis of the classification done by R. 
Lancefield in 1933 (Lancefield, 1933). S. agalactiae is a coccus with spherical 
shape and less than 2 μm in diameter. It is usually observed in pairs or short 
chains of cocci. It is catalase-negative, facultative anaerobic and β-hemolytic. It 
does not form spores and is not motile (Scanziani et al., 1999).  
 In the early 1930s, S. agalactiae was mainly recognized as a pathogen of 
dairy cattle, causing acute and chronic mastitis leading to reduced milk production 
(Keefe, 1997). Moreover, it was commonly isolated from the vagina of healthy 
women, but was considered a human commensal of the gastrointestinal and 
urogenital tract. By the end of the decade, some cases of fatal puerperal sepsis 
associated with GBS were reported (Fry, 1938). During the 1970s, interest in 
group B streptococci increased dramatically when this bacterium emerged as the 
leading cause of neonatal sepsis in nurseries throughout the U.S. (Franciosi et al., 
1973). Approximately 10%–35% of women are asymptomatic carriers of GBS 
(Barton et al., 1973). During delivery, newborns may become infected and 
develop severe diseases such as sepsis, pneumonia and meningitis (Schuchat, 
1998, Thigpen et al., 2011). In the 80s, the incidence of GBS infection was 
1.7/1000 newborns and the mortality was close to 50% (Boyer et al., 1983). In 
this decade, clinical trials demonstrated that the administration of intravenous 
antibiotics during labor, to women at risk of transmitting GBS to their newborns, 
could prevent early-onset disease (infection occurring in the first week of life) 
(Lim et al., 1986).  
 The guidelines for prevention of perinatal GBS disease are based on pre-
partum screening and prophylactic treatment with antibiotics (penicillin or 
erythromycin), and have been disseminated in different western countries since 
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the 90s. These measures have gradually reduced the incidence of early-onset 
disease to approximately 0.04% in USA. However, they are not sufficient to 
prevent late-onset disease (infection occurring in the period between the first week 
after birth and first 3 months of life) (Fig. 1) and invasive diseases in adult and 
elder people (Verani et al., 2010, Edwards & Baker, 2005). Overall, the case 
fatality rates from early-onset GBS disease have declined to 4–6% in recent years, 
as a consequence of improvements in therapy and management (Rodriguez-
Granger et al., 2012). And yet, in the western world, S. agalactiae represents the 
major cause of bacterial meningitis in newborns (Thigpen et al., 2011) (Fig. 2) 
and half of the infected suffer long-term neurodevelopmental defects (Rodriguez-
Granger et al., 2012). 
 No penicillin-resistant isolates of GBS have been observed so far, 
however, resistance to erythromycin and clindamycin has become relatively 
common in both genital tract isolates and invasive strains (Phares et al., 2008). 
Vaccination of adolescent or pregnant women is considered an attractive solution. 
 
 
FIGURE 1. Incidence of early- and late-onset invasive GBS disease in USA from 
1990 to 2008. Adapted from (Jordan et al., 2008). 
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FIGURE 2. Proportions of cases of bacterial meningitis reported in 2003–2007 
caused by each pathogen, according to age group. Mo, months; Yr, years. Adapted 
from (Thigpen et al., 2011). Copyright Massachusetts Medical Society. 
 
 
S. agalactiae pathogenesis 
 The pathogenesis of neonatal GBS infection begins with the asymptomatic 
colonization of the female genital tract. During labor the pathogen can be 
transmitted to the newborn (Schuchat, 1998), moreover, Bennett and coworkers 
reported that GBS can traverse placenta and weaken its membranes (Bennett et 
al., 1987) causing an increased risk of rupture of the placental membranes and 
preterm delivery or death of the fetus (Regan et al., 1996, Chen et al., 2013).  
 In newborns, early-onset infections occur in the first week after birth with 
symptoms typically starting in the first hours. These cases result from the 
ascension of GBS from the vagina to the amniotic fluid or from the contact with 
infected vaginal fluids during labor (Verani et al., 2010). During these processes 
GBS can be aspirated into the fetal lungs, potentially causing pneumonia and 
respiratory failure. From there, the organism can gain access to the bloodstream 
by passing through the alveolar epithelium (Fig. 3). Once in the bloodstream, 
GBS may cause septicemia and reaches the other organs and tissues. The lack of a 
completely functional immune system makes the neonates particularly prone to 
GBS invasive disease (Doran & Nizet, 2004). 
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 Late-onset infection occurs in infants up to 3 months of age, and is 
generally characterized by symptoms related to bacteremia and a high incidence 
of meningitis (Doran & Nizet, 2004). GBS causes meningitis thanks to its ability 
to traverse the human blood-brain barrier (Fig. 3) (Nizet et al., 1997). 
Prophylactic treatments have not reduced the incidence of these diseases (Verani 
et al., 2010) and the prevention of these infections is difficult. Children born from 
mothers without GBS-specific antibodies are more prone to acquire late-onset 
infection, both during delivery and hospitalization. Moreover, GBS strains 
isolated from infected neonates have been found in the mother’s breast milk 
suggesting this route as a possible mechanism of colonization (Le Doare & 
Kampmann, 2014, Olver et al., 2000).  
 Finally, GBS has emerged as an important pathogen also in other patient 
populations such as the elderly, pregnant women, diabetics and the 
immunocompromised (Doran & Nizet, 2004). Clinical manifestations of GBS 
infection in adults include skin, soft tissue and urinary tract infections, bacteremia, 
pneumonia, arthritis and endocarditis (Edwards & Baker, 2005). 
 
 
 
FIGURE 3. Stages in the molecular and cellular pathogenesis of neonatal GBS 
infection. Adapted from (Doran & Nizet, 2004).  
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S. agalactiae’s virulence factors  
 S. agalactiae is normally found in the gastrointestinal and urogenital tract, 
but during infection it colonizes other compartments such as the placental 
membranes, lung epithelium, the bloodstream and the brain (Doran & Nizet, 
2004, Nizet et al., 1997). Moreover, despite that GBS is an extracellular pathogen, 
it has been shown that invasion of human cells play an important role in 
pathogenesis (Lindahl et al., 2005). To survive and cause disease GBS has 
evolved a plethora of virulence factors which are involved in different critical 
points of the infectious process such as the adherence to and the penetration of the 
epithelial and endothelial cellular barriers, the avoidance of immunologic 
clearance mechanisms and the proinflammatory activity (Lindahl et al., 2005). 
GBS virulence factors are typically integral components of the bacterial surface or 
secreted extracellular components (Fig. 4).  
 A critical virulence factor involved in adhesion and invasion of cellular 
barriers is the -hemolysin/cytolysin (CylE). This pore-forming toxin is 
responsible for the lysis of red blood cells giving the typical clearer zone 
surrounding the GBS colonies when grown on blood agar plates. Moreover, this 
toxin lyses also other human cells such as lung epithelium and endothelial cells in 
the the blood-brain barrier (Nizet et al., 1997). The -hemolysin/cytolysin also 
has a role in inflammation, in fact, pore formation in macrophages can induce 
apoptosis and generation of ROS activating the sepsis cascade (Ring et al., 2000). 
Another pore-forming toxin of GBS is the CAMP factor. This secreted protein 
oligomerizes in the target membrane to form discrete pores and trigger cell lysis 
(Lang & Palmer, 2003). The hyaluronate lyase instead is a virulence factor that 
facilitate spread of bacteria by breaking down the hyaluronic acid polymers 
present in the extracellular matrices of the placenta and lung (Liu & Nizet, 2004).  
 Proteins important for GBS adhesion to epithelia include the Lmb adhesin 
which binds to laminin (Spellerberg et al., 1999), the surface anchored proteins 
FbsA and PavA mediating the binding to fibrinogen (Schubert et al., 2002, 
Mitchell, 2003) and the Rib protein (Stalhammar-Carlemalm et al., 1999). The 
C5a peptidase ScpB is a surface-localized serine protease involved both in 
adhesion to cells and in the avoidance of immunologic clearance. This protein 
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binds to fibronectin promoting bacterial adhesion and invasion of epithelial cells 
(Beckmann et al., 2002). Moreover, because of its protease activity, it inactivates 
human C5a, leading to attenuation of neutrophil chemotaxis (Hill et al., 1988). 
Another factor involved in avoidance of immunologic clearance is the 
streptococcal β-protein that captures to complement inhibitor protein factor H 
(Mitchell, 2003). 
 A non-proteinaceous virulence factor of GBS is the capsular 
polysaccharide (CPS). The CPS surrounds the external surface of the bacterium 
and is characterized by the presence of a terminal sialic acid identical to a sugar 
epitope widely displayed on the surface of mammalian cells. This epitope has 
evolved in GBS to resemble host ‘self’ and avoid immune recognition (Doran & 
Nizet, 2004). Moreover the CPS masks other antigenic determinants on the 
surface of the bacterium. Through this virulence factor, GBS is capable of 
preventing complement deposition and opsonophagocytosis (Hill et al., 1988). 
 
 
 
 
FIGURE 4. Summary of the main virulence factors of GBS. Adapted from (Mitchell, 
2003). 
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Prevention of GBS infection  
In most of the western countries pregnant women at 35-37 weeks of 
gestation are routinely screened for GBS carriage by vaginal and rectal swabs. 
Colonized women are treated before labor with oral erythromycin or intravenous 
penicillin to decrease the risk of vertical transmission. Other countries such as UK 
and Finland offer a less effective risk-based strategy at time of delivery (Colbourn 
et al., 2007, Homer et al., 2014). An interesting epidemiological study was 
conducted in 2007 by Colbourn and coworkers to determine the cost-effectiveness 
of prenatal strategies for preventing GBS in the UK (Colbourn et al., 2007). Based 
on the incidence of GBS infection in newborns from mothers with different risk 
factors, healthcare costs were calculated for several prevention strategies, 
including different prenatal screening and treatment regimens, and vaccination 
alone or in combination with the other measures. Results suggested that treatment 
with antibiotic for all the women and the screening of women with very low or 
absent risk factors would be the most cost-effective strategy. However, if a 
vaccine for GBS was available, vaccination for all and treatment of women with 
high risk factors would be the best choice. Vaccination would in fact reduce the 
antibiotic exposition and the consequent allergic reactions and antibiotic 
resistance (Colbourn et al., 2007). Moreover it may reduce the incidence of late-
onset GBS disease and infections of adults or the elderly (Edwards & Baker, 
2005).  
Currently, vaccination against GBS is in the early phases of development 
and various vaccines have been tested in women in Phase I and II trials (Baker et 
al., 1999, Paoletti & Madoff, 2002). Studies done in the 1970s demonstrated an 
association between low levels of maternal antibody to GBS and susceptibility of 
the newborn to GBS disease and showed that antibodies are transferred from 
mother to newborn (Baker & Barrett, 1973). Prenatal immunization is a strategy 
which has been shown to be safe and protective for both the mother and her 
fetus/infant (Steinhoff, 2013). For these reason the vaccination strategy proposed 
for GBS is to immunize mothers between 24 and 28 weeks of gestation. 
Vaccination is expected to induce mucosal immunity in the mother reducing 
maternal GBS colonization and transmission to the newborn. Moreover, 
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protective vaccine-induced antibodies crossing the placenta would protect the 
baby and are expected to persist in the infant for about 3 months after birth 
reducing late-onset infection (Colbourn et al., 2007, Chen et al., 2013). 
 Unfortunately, design of a Phase III efficacy trial to evaluate the safety and 
efficacy of maternal immunization to prevent GBS disease in infants presents 
some critical points that need to be considered. The low incidence of GBS 
newborn infections requires that the trial is conducted on a high number of 
mothers to obtain statistically significant results (Madhi et al., 2013). Moreover, 
given the current use of antibiotics for prenatal prophylaxis, it is unethical to 
design a placebo-controlled randomized clinical trial to determine the efficacy of 
the vaccine (Johri et al., 2006). Serological protection correlates could represent 
an answer to this problem, and efforts are ongoing to establishing an antibody 
threshold correlating with protection from GBS infections in newborn (Dangor et 
al., 2015).   
 
 
GBS vaccine candidates and molecular epidemiology 
 Initial attempts to develop a GBS vaccine focused on the use of the 
capsular polysaccharide as antigen. In the 1930s experiments demonstrated that 
polysaccharide-specific rabbit antibodies were protective against GBS infections 
when injected in mice (Lancefield, 1938).  
 Ten different variants of the capsular polysaccharide have been 
characterized so far (Ia, Ib, II-IX) (Cieslewicz et al., 2005, Berti et al., 2014) and 
these variants define the GBS serotypes. A recent epidemiological study on the 
distribution of GBS serotypes in developed countries showed that serotype III was 
the most frequently identified, followed by serotypes Ia, V, Ib and II (Fig. 5) and 
that the distribution of the serotypes changed very little in the last 30 years 
(Edmond et al., 2012, Rodriguez-Granger et al., 2012). In developing countries 
the distribution of the serotypes is slightly different, with prevalence of the 
serotypes Ia, II and III and a higher proportion of non-typeable isolates (approx. 
20%) (Johri et al., 2013). Serotype III is the most prevalent in newborn disease, 
accounting for half of the infections (Phares et al., 2008). A specific clone of this 
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serotype in particular, the clonal complex CC17, is strongly associated with 
neonatal meningitis (Bellais et al., 2012). For pediatric and adult cases, serotype 
V predominated (31% of cases), followed by serotypes Ia (Phares et al., 2008).  
  
 
 
 
FIGURE 5. Distribution of GBS serotypes in developed countries, 1980–2011. 
Adapted from (Edmond et al., 2012). 
 
 
 In the 1980s the first human clinical trials were conducted using the 
purified serotype III CPS from GBS as antigen. GBS CPS was demonstrated to be 
safe and immunogenic, but the immunological response was variable between 
subjects and the vaccine was not able to elicit B-cell memory (Baker et al., 1988). 
To overcome these problems, polysaccharides were conjugated to proteins. The 
first GBS glycoconjugate vaccine trial conducted in humans involved a serotype 
III CPS conjugated to tetanus toxoid (III–TT) (Kasper et al., 1996). Conjugate 
vaccines based on nine GBS serotypes have been prepared and tested pre-
clinically, although there is no cross protection between serotypes. For this reason 
capsular conjugate vaccines will need to be multivalent in order to provide 
sufficient coverage against the prevalent serotypes (Johri et al., 2006). Bivalent 
(II-TT, III-TT) and tetravalent (Ia-TT, Ib-TT, II-TT, III-TT) vaccines have been 
tested in humans and mouse and showed promising results (Baker et al., 2003, 
Paoletti et al., 1994). In order to achieve a 95% population coverage in Europe or 
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North America, five serotypes would need to be included (Ia, Ib, II, III and V) in a 
multivalent vaccine (Johri et al., 2006). However, there are regions such as Japan 
where this combination would not be appropriate due to the different distribution 
of serotypes (Lachenauer et al., 1999). 
 GBS proteins were also investigated as potential vaccine candidates to 
overcome the serotype specificity of the CPS antigen. The surface proteins tested 
included the C5a peptidase, Lmb, Sip, and LrrG which are present and highly 
conserved in all the serotypes. Promising results were obtained but further 
development of these vaccine candidates is uncertain (Johri et al., 2006). Reverse 
vaccinology strategies have also been used to identify immunogenic surface 
proteins that could confer protection from different serotypes showing that pilus 
components could represent good candidates (Maione et al., 2005). 
 
 
Biological relevance of bacterial capsules 
 The production of a capsular polysaccharide is a common feature of 
several pathogenic Gram-positive and -negative bacteria. As mentioned above, the 
primary function of these molecules is to shield the bacterial surface from 
interactions with the host immune system and prevent opsonophagocytosis (Hill et 
al., 1988). The importance of this virulence factor makes the CPS a very good 
vaccine candidate. Haemophilus influenza type b, Neisseria meningitidis, 
Streptococcus pneumoniae represent a few examples of encapsulated bacteria for 
which licensed vaccines have been developed using their capsular polysaccharides 
as antigens (Pace, 2013).  
 Isogenic GBS mutants lacking the capsule, or without the terminal sialic 
acid, were shown to bind greater amounts of C3b, to be more susceptible to killing 
by human neutrophils and to be less virulent in a neonatal rat model (Wessels et 
al., 1989, Marques et al., 1992). Despite the importance of this virulence factor, 
little is known about if and how GBS regulates CPS during the different steps of 
the pathogenesis. Studies have shown that the presence of the CPS is important 
for biofilm formation in an in vitro model (Xia et al., 2014), however, it is also 
reported that the CPS interferes with adhesion and invasion of cultured epithelial 
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and endothelial cells (Hulse et al., 1993, Tamura et al., 1994). These observations 
suggest that GBS may regulate the expression of the CPS in response to the host 
environment. The transcriptional regulators RogB and CovR/S of S. agalactiae 
were shown to regulate the transcription of the genes encoding the enzymes 
responsible for the CPS biosynthesis (Gutekunst et al., 2003, Lamy et al., 2004). 
Interestingly these two transcription factors regulate other virulence factors, 
however, the regulation of the CPS by them appears to be strain-specific and it is 
not clear whether differences in the transcription of the cps genes correlate with 
differences in CPS amount (Rajagopal, 2009). Analysis of GBS transcriptome in 
different growth conditions has only shown that the transcription of the cps genes 
is reduced when GBS is grown in human blood instead of laboratory medium 
(Mereghetti et al., 2008). Moreover, differences in doubling time during GBS 
growth have been observed to correlate with the amount of CPS produced, or 
more specifically, when GBS grows fast it appears to produce more CPS than 
when the growth is slower (Ross et al., 1999). It was also observed that when 
GBS is grown with a short doubling time it invades epithelial cells more 
efficiently (Malin & Paoletti, 2001). 
 Similarly to GBS, also other bacteria such as S. pneumoniae and N. 
meningitidis present this dual role of the CPS (Yother, 2011, Kugelberg et al., 
2008). In S. pneumoniae CcpA have been suggested as possible transcriptional 
regulator coordinating the CPS expression with the bacterial metabolism 
(Giammarinaro & Paton, 2002), and the function of some proteins of the CPS 
biosynthesis pathway have been shown to be affected by oxygen levels (Geno et 
al., 2014). Also in N. meningitidis some transcriptional regulators involved in 
CPS regulation are described (Kugelberg et al., 2008) and other mechanisms such 
as phase variation and transposon insertion events have been shown to alter the 
expression of the genes encoding the enzymes for the CPS biosynthesis (Uria et 
al., 2008). However, the detailed mechanisms used to regulate the expression of 
this important virulence determinant have yet to be established. 
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The biosynthesis of microbial polysaccharides  
Similar mechanisms are involved in the synthesis of capsular 
polysaccharides between different bacteria. In particular, the Wzy-, synthase-, and 
ABC transporter-dependent mechanisms occur in gram-negative bacteria 
(Whitfield, 2006), whereas only the Wzy- and synthase-dependent mechanisms 
are described in gram-positive bacteria (Yother, 2011). All these mechanisms are 
described in detail in two excellent reviews (Whitfield, 2006, Yother, 2011), but 
in this work we will focus only on the Wzy mechanisms which is the one used by 
GBS. 
The Wzy pathway is typical of polysaccharides with multiple different 
sugars and glycosidic linkages. This mechanism has been characterized in detail 
and described both for the CPS of S. pneumoniae (Yother, 2011) and for group 1 
and 4 capsules of E. coli (Whitfield, 2006). Figure 6 illustrates the Wzy pathway 
of S. pneumoniae which represents the prototype for Gram-positive bacteria. 
Briefly, the portal enzyme CpsE (WchA homology group) catalyzes the transfer 
of a sugar-1-P from a UDP-sugar to an undecaprenyl-phosphate lipid in the 
membrane. Then the basic repeating units of the CPS are synthesized at the 
cytosolic side of the membrane by processing other nucleotide diphospho-sugars 
and attaching them to the lipid anchored moiety. This is accomplished by the 
sequential action of glycosyltransferases. The units anchored to the membrane 
lipids are transferred to the outer side of the membrane by the flippase (Wzx 
homolog), where the polymerase (Wzy homolog) is responsible for the 
polymerization of the units into the full-length polysaccharide. The 
polysaccharide is then released from the undecaprenyl-phosphate and shed or 
covalently attached to the cell wall peptidoglycan by an unknown enzyme. The 
free undecaprenyl-phosphate is flipped back to the inside of the membrane and 
reused to synthesize another repeating unit (Yother, 2011). In Gram-negative 
bacteria a complex spanning the periplasmic space and the outer membrane is 
responsible for the transfer of the synthesized polysaccharide to the external 
surface of the bacteria (Cuthbertson et al., 2009). 
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FIGURE 6. The Wzy CPS biosynthesis pathway of S. pneumoniae. Glc, glucose; Rha, 
rhamnose; GlcUA, glucuronic acid; Und-P, undecaprenyl-phosphate; NDP-, nucleotide 
diphospho-. Adapted from (Yother, 2011). 
 
 
The cps operon 
 The genetic loci for the Wzy-dependent polysaccharide biosynthesis are 
similar in all the bacteria. The Wzy polymerase and Wzx flippase are the defining 
enzymes of this pathway and their presence in genetic loci is generally predicted 
by their putative membrane topologies (Yother, 2011). These two genes are 
usually quite conserved and are generally flanked by genes encoding enzymes 
unique to specific capsular serotypes in the different bacteria (Cieslewicz et al., 
2005, Yother, 2011). In S. pneumonia, for example, the enzymes of the Wzy-
dependent polysaccharide biosynthesis pathway are found in the cps operon. This 
operon presents a 5’ region encoding for proteins conserved among serotypes, a 
central region containing the genes for the polymerase, the flippase and the other 
serotype specific glycosyltransferases, and a 3’ variable region encoding enzymes 
responsible for the biosynthesis of specific sugar moieties or for their chemical 
modifications (Bentley et al., 2006, Yother, 2011).  
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 The cps locus of GBS was initially identified by Rubens and coworkers in 
a serotype III GBS strain by the use of a transposon mutant library (Rubens et al., 
1993). This locus has a general organization similar to the cps locus of S. 
pneumoniae. It is approximately 18 kb long and it is composed of 16-18 genes 
depending on the serotype (Cieslewicz et al., 2005). The locus is an operon 
transcribed in a single transcript starting from upstream the first gene (Yamamoto 
et al., 1999). The cps operon can be divided into three main regions (Cieslewicz et 
al., 2005). The central part of the operon (cpsE-L) determines the capsule serotype 
and comprises genes encoding for the glycosyltransferases, the polymerase (cpsH) 
and the flippase (cpsL). The last four genes of the operon (neuA-neuD) encode 
enzymes that synthesize the sialic acid. Finally, the first genes of the operon 
(cpsA-D) are not directly involved in the biosynthesis of the CPS repeating units 
(Cieslewicz et al., 2001) (Fig. 7). 
  
 
 
FIGURE 7. GBS cps operon. General organization of the cps operon of GBS. The 
example is from serotype Ia GBS.  
 
 
CpsABCD of S. agalactiae 
 The functions of the enzymes encoded by the central and the last portions 
of the cps operon have been identified experimentally or by homology 
(Yamamoto et al., 1999, Cieslewicz et al., 2005). They are all involved in the 
biosynthesis of the sialic acid, in the assembly and transport of the repeating units 
of the CPS and in their polymerization into the full-length polysaccharide. 
However, the function of the proteins encoded by the first four genes of the cps 
operon is still not clear. The genes cpsA-D are conserved among all the GBS 
capsule serotypes (>97% aa identity) and have orthologues in other encapsulated 
streptococci such as S. pneumoniae (Yamamoto et al., 1999). Their function in 
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GBS has been previously investigated by Cieslewicz and coworkers through the 
construction and characterization of knockout mutants. All the mutants retained 
the ability to produce the CPS although a clear reduction in the total amount of 
polysaccharide was observed for all the strains. A reduction in cps operon 
transcription was shown in the ΔcpsA mutant suggesting that CpsA may be 
required for transcription of the cps operon. Whereas, for CpsC and CpsD a more 
undefined role in polymerization/export of CPS have been was suggested 
(Cieslewicz et al., 2001). Lately, Hanson and coworkers showed that the 
recombinant CpsA bound the cps operon promoter in vitro, suggesting that this 
protein may be a transcription regulator (Hanson et al., 2012).  
 
 
CpsABCD homologues in other bacteria 
 Orthologues of the cpsABCD genes are found in several Gram-positive bacteria 
utilizing the Wzy pathway. In Gram-negative bacteria cpsA and cpsB orthologues are not 
present, while orthologues to CpsC and CpsD are readily identified. Interestingly, in 
Gram-negative bacteria CpsC and CpsD are found as the single multi-domain protein 
Wzc (Olivares-Illana et al., 2008, Whitfield & Paiment, 2003).  
 CpsA is a 485 aa membrane protein with a major extracellular portion (Hanson et 
al., 2011). This protein belongs to the LytR-CpsA-Psr (LCP) protein family, together 
with another two paralogues commonly found in Gram-positive bacteria. This family of 
proteins is suggested to be involved in the final steps of cell wall assembly (Hubscher et 
al., 2008) and the function of these proteins seems to partially overlap (Eberhardt et al., 
2012). The extracellular domains of the CpsA homologues of S. pneumoniae and B. 
subtilis have recently been crystallized and were proposed to be responsible for 
hydrolysis of the pyrophosphate linkage between the CPS and the undecaprenyl-
phosphate anchor (Kawai et al., 2011), and subsequent attachment of CPS to the 
peptidoglycan (Eberhardt et al., 2012). Interestingly, these functions appear different 
from those suggested for CpsA in GBS.  
 Concerning CpsBCD, orthologous proteins in S. pneumoniae (46-64% aa 
identity) were described to constitute a phosphoregulatory system which has been studied 
in some detail. The CpsD orthologue was shown to be a cytoplasmic autokinase that is 
trans- and cis-phosphorylating four tyrosines found in its C-terminal tail (Bender & 
Yother, 2001). The CpsC orthologue is a membrane protein with an uncharacterized 
 
 
24 
extracellular domain and an intracellular tail responsible for interaction with CpsD and 
consequent retention of the protein close to the membrane (Bender & Yother, 2001). 
Finally, the CpsB orthologue is the phosphatase of the system, and responsible for CpsD 
dephosphorylation (Bender & Yother, 2001, Hagelueken et al., 2009). Similarly, the Wzc 
protein of E. coli is composed of a membrane domain and a cytoplasmic autokinase 
domain (Whitfield & Paiment, 2003). Also in E. coli a phosphatase Wzb responsible for 
Wzc dephosporylation was found to be encoded in the wzy locus (Hagelueken et al., 
2009).  
 Despite that functional roles for these proteins have already been described, it has 
not been elucidated if/how this system is involved in CPS biosynthesis. S. pneumoniae 
strains with deletions in cpsB suggested ambiguous consequences of CpsD 
phosphorylation, with some studies reporting a reduced CPS production correlated with 
the increased phosphorylation (Morona et al., 2000) and others instead showing an 
increase in the amount of CPS produced (Bender et al., 2003). In E. coli Wzc 
oligomerizes in the inner membrane and interacts with the Wza oligomer spanning the 
outer membrane. In this complex, the cyclical phosphorylation of Wzc is suggested to 
regulate the processes of CPS polymerization and transport through the periplasmic space 
and outer membrane (Collins et al., 2007). In Gram-positive bacteria, CpsD cyclical 
phosphorylation is instead suggested to be responsible for regulating the two processes of 
CPS synthesis and attachment to the cell wall peptidoglycan (Kadioglu et al., 2008) but 
the mechanism of action has not been clearly established so far. 
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AIM OF THE THESIS 
 The capsular polysaccharide is the main virulence factor of GBS and is a 
promising antigen selected for the development of a vaccine to fight this 
pathogen. The chemical structure and the biological function of the CPS have 
been investigated in some detail, however very little is known about the 
biosynthesis of this molecule and about the regulation of this process.  
 The aim of this work is to investigate the role of the CpsABCD proteins 
encoded by the first four genes of the cps operon. These proteins are conserved 
between the different GBS serotypes and among bacteria synthesizing the CPS 
using the Wzy-pathway, but they are not predicted to be involved in the 
biosynthesis of the repeating units of sugars and in their polymerization. 
 Experimental studies investigating the role of CpsABCD in GBS are 
limited, and present potential discrepancies compared to S. pneumoniae and other 
related species. In GBS CpsA is suggested to be a transcriptional regulator of the 
cps operon, and CpsBCD are suggested to have a role in determining the 
characteristics of the CPS polymer. By homology, these three proteins are 
suggested to be members of a phosphoregulatory system but this putative function 
was never directly investigated in GBS. Moreover the specific role of this system 
in CPS biosynthesis has not been elucidated in any Gram-positive bacteria.   
 To investigate the role of these proteins we developed a panel of knockout 
and functional mutant strains, and analyzed the effects on cps operon 
transcription, CPS quantity, size, and attachment to the cell surface, as well as 
CpsD phosphorylation. In vivo molecular interactions between the CpsABCD 
proteins were also studied. The resulting data provided novel insights on the role 
of each individual protein, as well as their interdependencies, and showed that 
these proteins are responsible for balancing the processes of polymerization and 
attachment to the cell wall of the CPS. 
Moreover we took advantage of the differences in CPS phenotypes of 
selected mutant strains to investigate the biological impact of the CPS in the 
interaction with epithelial cells.  
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EXPERIMENTAL PROCEDURES 
Bioinformatic analysis 
 The aminoacid sequences of CpsA, CpsB, CpsC and CpsD of GBS 515 
(serotype Ia) were downloaded from the GeneBank Database (accession numbers 
EAO72243, EAO72192, EAO72213 and EAO72226). The protein sequences 
were analyzed using the online tool Pfam (http://pfam.xfam.org/ (Finn et al., 
2014)) to identify conserved domains. The predicted subcellular localization of 
the proteins was predicted using the online tool PSORTb 3.0.2 
(http://www.psort.org/psortb/ (Yu et al., 2010)). Subsequently the online tool 
Octopus (http://octopus.cbr.su.se/ (Viklund & Elofsson, 2008)) was used to 
predict the membrane topology of the predicted membrane proteins. Alignments 
with homologous proteins of S. pneumoniae and S. aureus were performed using 
Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/ (Sievers et al., 2011)). 
 
Bacterial strains and growth conditions.  
 GBS strains 515 and 515ΔcpsE were provided from Dr. Dennis Kasper 
(Harvard Medical School, Boston, MA, USA) and Dr Michael Cieslewicz 
(Cieslewicz et al., 2001) respectively. GBS strains were grown in Todd-Hewitt 
broth (THB) at 37°C, 5% CO2. Tryptic soy broth, 15 g/L agar (TSA) was used as 
solid medium. Strains were stored at -80°C in THB medium, 15% glycerol. MAX 
Efficiency® DH5α™ Competent Cells (Life Technologies) and chemically 
competent HK100 E.coli cells were prepared in-house, and used for 
transformation, propagation, and preparation of plasmids. Chemically competent 
BL21 and BTH101 E.coli cells were prepared in-house, and used for 
transformation, protein expression and for the Bacterial two Hybrid assay. E. coli 
was grown at 37°C with agitation (180 rpm) in Luria-Bertani broth (LB), or on 15 
g/L agar plates (LBA). Erythromycin (Erm) was used for selection of GBS (1 
µg/ml) or E. coli (100 µg/ml) containing the pJRS233-derived plasmids (Perez-
Casal et al., 1993) used for mutagenesis. Kanamycin (Kan) was used for selection 
of E. coli (50 µg/ml) containing the pET24b-derived plasmids (Novagen, South 
Africa) and the pKT25-derived plasmids (Euromedex, France). Ampicillin (Amp) 
 
 
28 
was used for selection of E. coli (100 µg/ml) containing the pUT18C-derived 
plasmids (Euromedex, France) and the pET15-derived plasmids (Novagen, 
Germany).  
 
Construction of GBS mutant strains 
 To prepare each mutant strain, the shuttle vector pJRS233 (Perez-Casal et 
al., 1993) containing the gene locus with an in-frame deletion or a codon 
substitution was constructed. Mutant strains obtained are described in Table 2, 
and primers used for the development of constructs are listed in Table 1. 
Constructs for genes with codon substitutions were prepared using a splicing by 
overlap extension PCR (SOEing-PCR) strategy (Horton et al., 1989). Briefly, 
amplicons up- and downstream of the codon substitution were amplified from 
GBS 515 gDNA using the PfuUltra II Fusion HS DNA Polymerase (Agilent 
Technologies). Internal primers used to amplify the two parts of the genes have 15 
bp overlapping tails and introduce the codon substitution, and amplicons are then 
joined together by SOEing-PCR. The resulting fragment was ligated into pJRS233 
using BamHI and XhoI restriction sites. 
 Constructs for genes with in-frame deletions were prepared using the 
Polymerase Incomplete Primer Extension (PIPE) method (Olsen & Eckstein, 
1989). Briefly, the gene and 900-1,000 bp up- and downstream of the coding 
sequence were amplified from GBS 515 gDNA and cloned into pET24b using 
NotI and XhoI (cpsA inserts) or BamHI and XhoI (cpsB-C-D inserts) restriction 
sites. In-frame deletions were developed by amplifying the plasmid using primers 
with 15 bp overlapping tails annealing at the two sides of the region to delete. 
Linear plasmids were transformed into HK100 competent cells able to re-
circularize the plasmid. Following propagation and purification of the plasmid, the 
inserts containing the in-frame deletions were transferred into pJRS233 plasmid 
by restriction digestion, ligation, and transformation of E. coli DH5α (Life 
Technology).  
 Constructs for chromosomal complementation were prepared by cloning 
the respective wt loci into pJRS233.The various pJRS233 constructs were used for 
insertion/duplication and excision mutagenesis (Fig. 8) (Perez-Casal et al., 1993, 
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Cieslewicz et al., 2001). Briefly, pJRS233-derived plasmids purified from E. coli 
were used to transform electrocompetent GBS 515 cells by electroporation 
(Framson et al., 1997). Transformants were selected by growth on TSA + Erm at 
30°C for 48 h. Integration was performed by growth of transformants at 37°C 
(non-permissive temperature for the suicide shuttle vector) with Erm selection. 
Excision of the integrated plasmid was performed by serial passages in THB at 
30°C, and parallel screening for Erm-sensitive colonies on plate. Mutants were 
verified by PCR sequencing of the loci.  
 
 
 
FIGURE 8. Mutagenesis strategy used to develop GBS mutant strains. Cartoon 
representing the insertion/duplication and excision mutagenesis strategy commonly used 
to develop GBS mutant strains.  
 
 
Growth curves 
 Bacteria were inoculated 1:50 from O/N cultures into 200 µl of fresh THB 
and grown on plate at 37°C. Each strain was inoculated into five independent 
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wells. OD600 was monitored every 20 min for 400 min using a plate reader 
(TECAN, Switzerland). Growth curves have been designed by plotting the mean 
of the ODs measured at each time point for the five biological replicates.  
 
qRT-PCR analysis 
 RNA extracts were prepared as described (Faralla et al., 2014). Briefly, 
bacteria were harvested at two time points, at OD600=0.4 (log phase) and 
OD600=1.7 (early stationary phase). To rapidly arrest transcription, 10 ml of 
bacteria were cooled on ice and added to 10 ml of frozen THB medium in a 50 ml 
conical tube. GBS cells were then collected by centrifugation for 15 min at 3,220 
g, 4°C, and resuspended in 800 µl of TRIzol (Life Technologies). Bacteria were 
disrupted mechanically by agitation with Lysing matrix B in 2 ml tubes (MP 
Biomedicals, Santa Ana, CA) using a Fastprep-24 homogenizer (MP Biomedicals, 
Santa Ana, CA) for 60 s at 6.5 m/s for two cycles, and kept on ice for 2 min 
between the cycles. Samples were then centrifuged for 5 min at 8,000 g, 4°C and 
RNA was extracted with Direct-zol™ RNA MiniPrep kit (Zymo Research, Irvine, 
CA) according to the manufacturer’s instructions. RNA samples were treated with 
DNase (Roche) for 2 h at 37°C and further purified using the RNA MiniPrep kit 
(Qiagen), including a second DNase treatment on the column for 30 min at room 
temperature (RT), according to the manufacturer’s instructions. cDNA was 
prepared using the Reverse Transcription System (Promega) by using 500 ng of 
RNA per reaction. Real time quantitative PCR (qRT-PCR) was performed on 50 
ng of cDNA that was amplified using LightCycler
®
 480 DNA SYBR Green I 
Master (Roche). Reactions were monitored using a LightCycler
®
 480 instrument 
and software (Roche). Three technical replicates were monitored for each 
strain/condition analyzed. To quantify cps operon transcription level, primers 
annealing on cpsA and cpsE were used for all the strains with the exception of 
cpsA mutants where primers for cpsD and cpsE were used. The transcript amounts 
in each condition were standardized to an internal control gene (gyrA) and 
compared with standardized expression in the wild-type (wt) strain (CT 
method). The primers used are listed in Table 1. 
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Production of α-CpsA, α-CpsB and α-CpsD mouse sera 
 The cpsB and the cpsD genes were amplified from GBS 515 gDNA. For 
cpsA only the portion of the gene codifying for the extracellular part of CpsA was 
amplified. Primers used to amplify the genes are listed in the Table 1. The cpsA 
and cpsD inserts were cloned by PIPE method (Olsen & Eckstein, 1989) into a 
modified pET-15 vector (Novagen), enabling the expression of the protein with an 
N-terminal 6xHis-tag followed by a cleavage site for the TEV (tobacco etch virus) 
protease. The cpsB insert was cloned by restriction enzymes digestion (NdeI and 
XhoI) into the pET24b vector (Novagen), enabling the expression of the protein 
with a C-terminal 6xHis-tag. Plasmids were propagated in E. coli DH5α. 
Subsequently, the plasmids were transformed into E. coli BL21(DE3) cells 
(Novagen) where the expression of the 6xHis-tagged fusion proteins were induced 
according to the manufacturer’s instructions. The bacterial pellet was resuspended 
in 50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 10 mM imidazole, and was lysed by 
sonication. Extracts were pelleted and the supernatant was purified using a FF-
Crude His-Trap HP nickel chelating column (GE Healthcare, Little Chalfont, 
United Kingdom). The recombinant proteins were eluted with 300 mM imidazole, 
and the buffer was exchanged to PBS using an Amicon Ultra 3K centrifugal filter 
(Millipore, Cork, Ireland). Antisera specific for CpsA, CpsB and CpsD were 
produced by immunizing (prime and two boost) 8 CD1 mice with 20 µg of 
purified recombinant protein formulated with 400 µg of Alum. 
 
Protein extracts 
 Bacteria were grown in 30 ml THB at 37°C until exponential growth phase 
was reached (OD600 = 0.4). Cells were pelleted, washed in PBS and resuspended 
in 800 µl of Tris-HCl 50 mM pH 7.5 with cOmplete Protease Inhibitor and 
PhosSTOP Phosphatase Inhibitor Cocktail Tablets (Roche), transferred into 
Lysing Matrix B 2 ml Tubes (MP Biomedicals, Santa Ana, CA) and lysed using 
the FastPrep-24™ Automated Homogenizer (6 cycles at 6.5 m/s for 30 s). Tubes 
were centrifuged 500 g for 5 s, the supernatant was collected and further 
centrifuged at max speed for 15 min at 4°C to separate the soluble fraction 
(supernatant) from the total fraction (pellet).  
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Flow cytometry 
 Flow cytometry using α-CPSIa mAb was performed as described 
elsewhere (Berti et al., 2014) with minor differences. Briefly, bacteria were grown 
overnight on TSA plates at 37°C, harvested using a sterile loop and diluted in PBS 
to OD600 = 0.3. The bacterial suspension (400 µL) was centrifuged at 8,000 g, 
resuspended in 200 µl of heat-inactivated fetal calf serum and incubated for 20 
min at RT with shaking. Bacteria were diluted 1:10 in PBST, 0.1% BSA with 
1:10,000 diluted α-CPSIa and incubated for 1 h at 4°C. Samples were washed 
twice in PBST, resuspended in goat anti-mouse allophycocyanin (APC)-
conjugated F(ab’)2 fragment IgG (Jackson ImmunoResearch, West Grove, PA) 
diluted 1:200 in PBST, and incubated for 30 min at 4°C. Bacteria were washed 
twice in PBS, fixed in PBS, 2% paraformaldehyde for 20 min at RT, centrifuged 
and resuspended in 150 µl PBS. All data were collected using a FACS CANTO II 
(BD) by acquiring 10,000 events, and data analysis was performed with Flow-Jo 
software (v.8.6, TreeStar Inc., Ashland, OR). 
 
Quantification of the capsular polysaccharide attached to the cell surface 
 Alkaline extraction of CPS from GBS bacteria was performed as 
previously described (Wessels et al., 1990). Briefly, bacteria were grown in 50 ml 
THB at 37°C for 8 h (stationary phase). Viable counts were performed and 
confirmed that CFU numbers between the strains were comparable. GBS cells 
were collected by centrifugation for 15 min at 3,220 g at 4°C, resuspended in 1.1 
ml of PBS, 0.8 N NaOH and incubated at 37°C for 36 h. Samples were neutralized 
by addition of HCl and pelleted by centrifugation for 10 min at 10,000 g, 4°C. 850 
µl of the supernatant were diluted in 7.15 ml of water, and centrifuged for 10 min 
at 3,220 g at 4°C. 7.2 ml of the supernatant were loaded on a Vivaspin 10 tube 
(Sigma) and centrifuged at 3,220 g until most of the solution passed through the 
membrane. After two washes with 1 ml dH2O, the CPS extract was recovered 
from the membrane by resuspension in 1.6 ml of water. The amount of CPS 
present in the extract was estimated by measuring the sialic acid content using the 
colorimetric resorcinol-hydrochloric acid method (Svennerholm, 1957). Briefly, 
120 µl of extract were mixed with 380 µl of water and 500 µl of resorcinol 
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solution (0.2% resorcinol, 0.3 mM copper sulfate, 30% (v/v) HCl). Samples were 
boiled for 20 min, cooled to room temperature and absorbance was measured at 
564 nm. The sialic acid content of the samples was then determined by 
comparison with a concomitantly prepared standard curve using serial dilutions of 
purified sialic acid.  
 
Quantification of CPS in the growth medium 
 Bacteria were grown in 10 ml THB at 37°C for 8 h. GBS cells were 
pelleted by centrifugation for 15 min at 3,220 g at 4°C, and the growth medium 
was collected and filtered using a 0.22 µm Nalgene Syringe Filter (Thermo 
Scientific). The amount of capsular polysaccharide released in the growth medium 
was estimated by dot blot. Serial dilutions (1:2) were prepared in PBS. Two µl of 
each serial dilution were spotted onto a nitrocellulose membrane. The membrane 
was dried for 20 min and blocked by soaking in 5% skim milk in PBS, Tween-20 
0.05% (PBST). Detection by immunoblotting was performed as described below 
(immunoblotting experiments).  
 
Cell wall extracts  
 Bacteria were grown in 10 ml THB at 37°C for 8 h. GBS cells were 
pelleted by centrifugation for 15 min at 3,220 g at 4°C and washed in PBS. 
Extracts of CPS attached to the peptidoglycan were prepared by incubating the 
bacterial pellet with 200 U of mutanolysin (Sigma) diluted in 50 µl of 
protoplasting buffer (0.1 M potassium phosphate, 40% sucrose, 10 mM MgCl2) 
for 1 h at 37°C. 20 µl of Proteinase K solution (Life Technologies) were added, 
and samples were incubated at 56°C for 30 min. After centrifugation for 5 min at 
10,000 g at 4°C the supernatant was collected. 
 
Immunoblotting experiments  
 CPS or protein extracts were separated by electrophoresis on NuPage 4-
12% Bis-Tris gels (Life Technologies) according to the manufacturer’s 
instructions. Western blot was performed using the iBlot® Blotting System (Life 
Technologies) according to the manufacturer’s instructions. Nitrocellulose 
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membranes were blocked by soaking in 5% (w/v) skim milk in PBST with the 
exception of membranes probed with the α-P-Tyr mAb, which were blocked in 
3% (w/v) BSA in PBST. Primary mouse α-CPSIa mAb (30E9/B11), were 
obtained by immunization with Ia glycoconjugate. Mouse α-P-Tyr mAb (Sigma, 
clone PT-66), mouse α-RNA polymerase  mAb (Thermo Scientific, clone 
8RB13) and mouse α-CpsA, α-CpsB and α-CpsD polyclonal sera were also used 
as primary antibodies. All the primary antibodies and sera were diluted 1:2,000 in 
1% (w/v) BSA in PBST and membranes were incubated for 1 h at RT. After three 
5 min washes in PBST, membranes were incubated in 1:15000 of secondary goat 
anti-mouse antibody conjugated to horseradish peroxidase. Detection was 
performed using the SuperSignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) according to the manufacturer’s instructions. 
 
Immunogold labelling and electron microscopy 
 Immunogold electron microscopy of the GBS CPS in wt and mutant 
strains was performed as previously described (Barocchi et al., 2006). Briefly, 
bacteria were grown in THB until exponential growth phase was reached (OD600 = 
0.4). Cells were pelleted, washed in PBS and fixed in PBS, 2% paraformaldehyde 
for 20 min at RT. Twenty µl of sample were added to 200-square mesh formvar 
copper grids coated with a thin carbon film (Ted Pella, Redding, CA) and 
incubated at RT for 5 min. The excess of solution was blotted by Whatman filter 
paper. The grids were than incubated for 1 hin blocking buffer (1% normal rabbit 
serum, 1% BSA, 1× PBS), and subsequently incubated with 1:1,000 α-CPSIa 
mAb in blocking buffer. Samples were washed five times for 5 min in blocking 
buffer and incubated with secondary gold-conjugated antibodies at 1:40 (goat 
anti-mouse IgG, 10 nm (Agar Scientific, UK)). Samples were washed in distilled 
water five times for 5 min each and blotted. Grids were stained for 45 sec with 
aqueous 1% uranyl acetate pH 4.5, blotted, air dried at RT, and finally observed in 
a FEI Tecnai G2 spirit operating at voltage of 80 kV and at a magnification of 
87,000. Images were collected with a CCD Olympus.SIS Morada 2K*4K*. 
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Purification of capsular polysaccharide from bacterial pellets and spent 
media 
 The 515 strain and the ΔcpsA, CpsC(Δext) and CpsD(K49A) mutant 
strains were grown in 1 liter THB at 37°C for 8 h. The pellet and the medium 
obtained from the cultures were separated by centrifugation for 30 min at 8,600 g 
at 4°C. The purification process was based on previously described procedures 
(Wessels et al., 1990). Briefly, pellets were washed in PBS and successively 
inactivated by incubation with PBS, 0.8 N NaOH at 37°C for 36 h. After 
centrifugation at 4,000 rpm for 20 min, 1 M Tris buffer (1:9, v/v) was added to the 
supernatant and diluted with 1:1 (v/v) HCl to reach a neutral pH. Spent growth 
media were inactivated by filtration 0.22 µm. For both bacterial pellets and media 
the same purification process was applied. Briefly, 2 M CaCl2 (0.1 M final 
concentration) and ethanol (30% v/v final concentration) were added to the 
solution. After centrifugation at 4,000 g for 20 min, the supernatants were 
subjected to a tangential flow filtration on a 30,000-molecular weight cutoff 
(Hydrosart Sartorius, 50 cm
2
 surface) against 16 volumes of 50 mM TRIS, 500 
mM NaCl, pH 8.8, and 8 volumes of 10 mM sodium phosphate, pH 7.2. Then, the 
samples were loaded in a preparative size exclusion column (Sephacryl S500 
column, GE Healthcare) by using 10 mM sodium phosphate, 500 mM NaCl pH 
7.2 as eluent buffer. The CPS samples were subjected to full N-acetylation. After 
complete drying, samples were solubilized in 300 mM Na2CO3/300 mM NaCl pH 
8.8. A 1:1 diluted solution of 4.15 μL/mL acetic anhydride in ethanol was added, 
and the reaction was incubated at room temperature for 2 h. Samples were then 
purified in a preparative size exclusion column (Sephadex G15 column, GE 
Healthcare) by using MilliQ water. The polysaccharide content was determined 
using the colorimetric resorcinol-hydrochloric acid assay (Svennerholm, 1957). 
The purity of the polysaccharide preparation was assessed by colorimetric assays, 
which indicated a content of residual proteins below 3% (w/w) and nucleic acids 
below 1% (w/w). Endotoxin content was <30 endotoxin units/μg of saccharide, 
measured by the Limulus amebocyte lysate (LAL) test.  
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NMR Spectroscopy 
 
1
H NMR experiments were recorded by a Bruker Avance III 400 
spectrometer, equipped with a high precision temperature controller, and using 5-
mm broadband probe (Bruker). TopSpin software (v.3.2, Bruker) was used for 
data acquisition and processing. 
1
H NMR spectra were collected at 25 +/- 0.1°C 
with 32,000 data points over a 10 ppm spectral width, accumulating an 
appropriate number of scans for high signal/noise ratio. The spectra were 
weighted with 0.2 Hz line broadening and Fourier-transformed. The transmitter 
was set at the water frequency which was used as the reference signal (4.79 ppm). 
All monodimensional proton NMR spectra were obtained in a quantitative manner 
using a total recycle time to ensure a full recovery of each signal (5 x 
Longitudinal Relaxation Time T1). 
 
HPLC-SEC 
 CPS samples were eluted on a TSK gel 6000PW (30 cm × 7.5 mm) 
column (particle size, 17 μm; Sigma 8-05765) with TSK gel PWH guard column 
(7.5 mm ID × 7.5 cm L; particle size, 13 μm; Sigma 8-06732) (Tosoh Bioscience) 
and calibrated with a series of defined pullulan standards (Polymer) of average 
molecular weights ranging from 20,000 to 1,330,000 Da. Void and bed volume 
calibration was performed with λ-DNA (λ-DNA Molecular Weight Marker III, 
0.12–21.2 kbp; Roche) and sodium azide (NaN3) (Merck), respectively. The 
mobile phase was 10 mM sodium phosphate pH 7.2, at a flow rate of 0.5 mL/min 
(isocratic method for 50 min). The polysaccharide samples were analyzed at a 
concentration of 0.2-0.4 mg/mL, using 10 mM sodium phosphate buffer pH 7.2 as 
mobile phase, at a flow rate of 0.5 mL/min. 
 
Bacterial two-hybrid 
 A bacterial two-hybrid assay (BACTH) was employed to test potential 
interactions between CpsA, CpsC and CpsD (Karimova et al., 1998). CpsC, CpsD 
and CpsA coding sequences were amplified using the primers described in Table 
1 and cloned into pUT18C and pKT25 plasmids (Euromedex, France) at the C-
terminal of the domains T18 and T25 of the adenylate cyclase of Bordetella 
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pertussis. CpsC was cloned both in a full length version and with the C-terminal 
33-aa tail deleted. The nucleotide sequences of the modified regions of the 
plasmids were confirmed by sequencing. Interactions between proteins were 
tested by introducing the plasmids into the adenylate cyclase-deficient 
Escherichia coli strain BTH101 (Euromedex, France). Empty plasmids were 
tested together with all the fusion proteins as negative control. Positive control 
plasmids pKT25-zip and pUT18C-zip were provided by the manufacturer 
(Karimova et al., 1998). Colonies containing both plasmids were selected by 
plating on LB + Kan 50 µg/ml + Amp 100 µg/ml agar plates and growing them 
overnight (O/N) at 37°C. Four colonies were selected for each transformation and 
independently inoculated into 1 ml of LB, 50 µg/ml Kan, 100 µg/ml Amp, 1 mM 
IPTG and grown O/N at 30°C. Two µl from each culture spotted onto LB agar 
plates with additives as seen above and 80 µg/ml X-gal. After incubation O/N at 
30°C, the plates were examined for the formation of blue colonies, indicative of a 
protein-protein interaction.  
 
Biofilm formation assay on polystyrene plates 
 The biofilm formation assay was performed as described (Rinaudo et al., 
2010). GBS strains grown to stationary phase in THB, 1% glucose were diluted 
1:50 in fresh medium and 100 µl cultures were inoculated into a polystyrene flat-
bottom 96-well plate (Costar). Plates were incubated without shaking at 37°C for 
18 h aerobically in 5% CO2. Media, including any unattached bacteria, were 
decanted from the wells. Wells were washed with PBS and subsequently air-dried. 
Adherent bacteria were stained for 10 min with a 0.5% (w/vol) solution of Crystal 
Violet. After rinsing three times with PBS, bound dye was released from stained 
cells using 30% glacial acetic acid. This allowed indirect measurement of biofilms 
formed on both the bottom and sides of the well. Biofilm formation was 
quantified by measuring absorbance of the solution at 545 nm with a microplate 
reader (Tecan, Switzerland). The assay was run in five replicates for three times. 
 
In vitro adhesion/invasion assay 
 An in vitro adhesion/invasion assay was performed as described (Korir et 
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al., 2014). The A549 cell line (ATCC CCL-185), a human alveolar epithelial 
carcinoma cell line, was maintained by incubation at 37°C with 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) (Gibco) containing 10% fetal 
bovine serum (FBS) (Gibco) and 0,2% Primocin (InvivoGen, France). Passages 
from 12-18 were used for the assay. The day before the experiment cells were 
trypsinized, resuspended in infection medium (DMEM, 10% FBS and no 
antibiotics), plated on a 24-well plate (2x10
5
 cells/well) and incubated for 24 h at 
37°C with 5% CO2. GBS strains were grown in THB to exponential phase, 
washed once with PBS and resuspended in infection medium. Prior to infection, 
host cells were washed with PBS. Then, they were infected with bacteria using a 
multiplicity of infection (MOI) of one bacterial cell per host cell. After 2 h of 
incubation at 37°C with 5% CO2, wells were washed five times with PBS to 
remove non-adherent bacteria. To determine the number of associated bacteria 
(attached and invaded), host cells were lysed with cold PBS, 1% saponin (Sigma) 
for 10 min. Lysates were subjected to vortex mixing and plated on TSA plates 
after serial dilutions in PBS. Plates have been incubated overnight at 37°C, and 
CFU were counted. To test invasion, infection medium containing 100 µg/ml of 
gentamicin (Gibco) and 5 µg/ml of penicillin G (Sigma) was added to each well 
and incubated at 37°C for another 2 h to kill extracellular bacteria. Wells were 
then washed five times with PBS, and intracellular bacteria were enumerated as 
described above. All data were expressed as percentages of the total number of 
bacteria per well after the 2-h infection. The ratio between invaded and associated 
bacteria was also calculated. Assays were run in triplicate at least three times. 
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TABLE 1. Oligonucleotides. Restriction sites are marked in bold, overlapping regions 
used for mutagenesis are underlined, nucleotidesubstitutions resulting in amino acid 
substitutions are marked in bold and underlined. For, forward; Rev, reverse; Ampl., 
amplification.  
 
Name Sequence Description 
NotA5F TAAAGCGGCCGCCTCTATCACTGACAACAATGG Ampl. of cpsA + flanking regions, 
For, 894 bp upstream cpsA start, 
NotI  
XhA3R TATCCTCGAGGAAGAAGTATATTGTGGCGTA Ampl. of cpsA + flanking regions, 
Rev, 916 bp downstream cpsA end, 
XhoI 
KOA3F TCGCGCCGTCAACAAAAGAACACAATGGAGGAATAAC ΔcpsA mutagenesis, For, overlap 
KOA5R 
KOA5R TTGTTGACGGCGCGAATGATTAGACATTGTAA ΔcpsA mutagenesis, Rev, overlap 
KOA3F 
M1A3F ACTACTTTATATGGATAACAAGAATGATTGATATTCATTC CpsA(Δext) mutagenesis, For, 
overlap M1A5R 
M1A5R TCCATATAAAGTAGTAGCAACGAAAATAGAAGC CpsA(Δext) mutagenesis, Rev, 
overlap M1A3F 
M2A3F TCTATATTAGCGGTTAACAAGAATGATTGATATTCATTCTC CpsA(ΔLyt-R) mutagenesis, For, 
overlap M2A5R 
M2A5R ACCGCTAATATAGATATTAAATACCCCTTCTTTATG CpsA(ΔLyt-R) mutagenesis, Rev, 
overlap M2A3F 
BaB5F TAAAGGATCCTTATGTTAGCTTAATTGAACTTAGCA Ampl. of cpsB + flanking regions, 
For, 904 bp upstream cpsB start, 
BamHI 
XhB3R AAAGCTCGAGGACATAACAGAGTTCCTAGTA Ampl. of cpsB + flanking regions, 
Rev, 960 bp downstream cpsB end, 
XhoI 
KOB3F ATTCATTCTCATATCCATTACATTTAGGAGATTTCATGAA ΔcpsB mutagenesis, For, overlap 
KOB5R 
KOB5R GATATGAGAATGAATATCAATCATTCTTGTTATTCCTC ΔcpsB mutagenesis, Rev, overlap 
KOB3F 
M1BF GTTGCGCATATAGAGGCGTATAACGCTTTAGA CpsB(R139A) mutagenesis, For, 
overlap M1BR 
M1BR TCTAAAGCGTTATACGCCTCTATATGCGCAAC CpsB(R139A) mutagenesis, Rev, 
overlap M1BF 
M2BF CATAACCTTGATGTTGCACCGCCATTTTTAGC CpsB(R206A) mutagenesis, For, 
overlap M2BR 
M2BR GCTAAAAATGGCGGTGCAACATCAAGGTTATG CpsB(R206A) mutagenesis, Rev, 
overlap M2BF 
BaC5F ACAAGGATCCACTGTCGAGTCACAAGCATTA Ampl. of cpsC + flanking regions, 
For, 905 bp upstream cpsC start, 
BamHI 
XhC3R CAATCTCGAGTTAAACTCTTCAAGATAGCCACG Ampl. of cpsC + flanking regions, 
Rev, 943 bp downstream cpsC end, 
XhoI 
KOC3F ATGAATAAAATAGCTATAGTACCAGATTTGAATAAACTT ΔcpsC mutagenesis, For, overlap 
KOC5R 
KOC5R AGCTATTTTATTCATGAAATCTCCTAAATGTAATGGT ΔcpsC mutagenesis, Rev, overlap 
KOC3F 
M1C3F ATTATGGGTATTTTGTAAGGAGAATATAATGACTCGTT CpsC(ΔC-term) mutagenesis, For, 
overlap M1C5R 
M1C5R CAAAATACCCATAATAACTAAAACAATAGTTGATAATCC CpsC(ΔC-term) mutagenesis, Rev, 
overlap M1C3F 
M2C3F TCAACAAGGATATATGTTACTCAAGTAGAGGATATC CpsC(Δext) mutagenesis, For, 
overlap M2C5R 
M2C5R ATATATCCTTGTTGAAGAAGTATATTGTGGCGTAA CpsC(Δext) mutagenesis, Rev, 
overlap M2C3F 
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Name Sequence Description 
BaD5F TTTAGGATCCCAAAAAGAACGGGTGAAGGAA Ampl. of cpsD + flanking regions, 
For, 1018 bp upstream cpsD start, 
BamHI 
XhD3R TCTACTCGAGCTACCATTACGACCTACTCTA Ampl. of cpsD + flanking regions, 
Rev, 966 bp downstream cpsD end, 
XhoI 
KOD3F GAAATAGTTGATAGCAAAAGGGATAGAAAAAGGAAGTAA ΔcpsD mutagenesis, For, overlap 
KOD5R 
KOD5R GCTATCAACTATTTCTAAACGAGTCATTATATTCTC ΔcpsD mutagenesis, Rev, overlap 
KOD3F 
M1DF GGAAGGGGAAGGAGCATCCACTACTTCA CpsD(K49A) mutagenesis, Rev, 
overlap M1DR 
M1DR TGAAGTAGTGGATGCTCCTTCCCCTTCC CpsD(K49A) mutagenesis, For, 
overlap M1DF 
M2D3F GTTAGTGAATCTGTTGGAAAAAGGGATAGAAAAAGG CpsD(ΔP-Tyr) mutagenesis, For, 
overlap M2D5R 
M2D5R AACAGATTCACTAACTTTATTAAGAATAATACCTAAGAAC CpsD(ΔP-Tyr) mutagenesis, Rev, 
overlap M2D3F 
1015F AGGTTTACTTGTGGCGCTTG qRT-PCR, For, annealing to gyrA 
1015R TCTGCTTGAGCAATGGTGTC qRT-PCR, Rev, annealing to gyrA 
1292F TCAACTGGACAACGCTTCAC qRT-PCR, For, annealing to cpsA 
1292R AAGTTGAGCTCCTGGCATTG qRT-PCR, Rev, annealing to cpsA 
1288F TGCTCATATGTGGCATTGTG qRT-PCR, For, annealing to cpsE 
1288R AGAAAAGATAGCCGGTCCAC qRT-PCR, Rev, annealing to cpsE 
1289F TCAATGCGATCCGTACAAAC qRT-PCR, For, annealing to cpsD 
1289R GTGGATTTTCCTTCCCCTTC qRT-PCR, Rev, annealing to cpsD 
CF TAGGGGATCCCATGAATAAAATAGCTAATACAG BACTH, For, ampl. of cpsC, 
BamHI 
CR CATTAGAATTCGATTAAAGTTTATTCAAATCTGG BACTH, Rev, ampl. of cpsC, 
EcoRI 
CMutR CATTAGAATTCGATTACAAAATACCCATAATAAC BACTH, Rev, ampl. of CpsC(ΔC-
term), EcoRI 
DF AGGAGGATCCCATGACTCGTTTAGAAATAG BACTH, For, ampl. of cpsD, 
BamHI 
DR TACAGAATTCGATTACTTCCTTTTTCTATC BACTH, Rev, ampl. of cpsD, 
EcoRI 
AF GGAGGGATCCAATGTCTAATCATTCGCGCCG BACTH, For, ampl. of cpsA, 
BamHI 
AR ATCAGGTACCCTTGTTATTCCTCCATTGTGTTC BACTH, Rev, ampl. of cpsA, KpnI 
AextF CTGTACTTCCAGGGCTCAACCATTGATTTGACAAATAATC 
Recombinant extracellular domain 
of CpsA, For, ampl. of cpsA, 15pb 
overlap with pET-TEV  
AextR AATTAAGTCGCGTTATTCCTCCATTGTGTTCTT 
Recombinant extracellular domain 
of CpsA, Rev, ampl. of cpsA, 15pb 
overlap with pET-TEV  
1291f AACACATATGATTGATATTCATTCTCAT 
Recombinant CpsB, For, ampl. of 
cpsB, NdeI 
1291r AATCTCGAGAATGTAATGGTTTTTTAATATAG 
Recombinant CpsB, Rev, ampl. of 
cpsB, XhoI 
1289f CTGTACTTCCAGGGCATGACTCGTTTAGAAATAGTTGATAGC Recombinant CpsD, For, ampl. of 
cpsD, 15pb overlap with pET-TEV  
1289r AATTAAGTCGCGTTACTTCCTTTTTCTATCCCTTTTTCCGTAA Recombinant CpsD, Rev, ampl. of 
cpsD, 15pb overlap with pET-TEV  
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RESULTS 
Bioinformatic analysis of CpsABCD proteins of S. agalactiae 
 The amino acid sequences of CpsABCD of GBS 515 (serotype Ia) were 
analyzed using Pfam to identify conserved domains. The online tool PSORTb was 
used to predict the subcellular localization and subsequently Octopus was used to 
predict the membrane topology of the membrane proteins. Results from these 
analyses are summarized in the cartoon in figure 9 and were consistent with 
previous literature on S. agalactiae and S. pneumonia (Hanson et al., 2012, Byrne 
et al., 2011).  
 CpsA is predicted to be a membrane protein with intracellular N-terminus 
and extracellular C-terminus. Three putative transmembrane helices are found 
among the first 96 aa of the protein, and the latter 389 aa are predicted to be 
extracellular. In the extracellular portion of the protein two conserved domains are 
identified, the proximal DNA polymerase processivity factor domain (DNA_PPF, 
Pfam accession no. PF02916) and the distal LytR_cpsA_psr domain (Pfam 
accession no. PF03816). As reported by Hanson and coworkers (Hanson et al., 
2012), the identification of the DNA_PPF domain is curious because the sequence 
of CpsA is very divergent from traditional DNA_PPF sliding clamp, moreover 
proteins belonging to this family bind directly to DNA, and in CpsA this domain 
is extracellular. Therefore, the function of this domain in CpsA is unknown. As 
for the LytR_cpsA_psr domain, it is found in the extracellular domain of a 
number of putative membrane-bound proteins related to the cell envelope, but its 
function is annotated as unknown. 
 CpsB is predicted to be localized in the cytoplasm and to possess a 
Polymerase and Histidinol Phosphatase domain (PHP, Pfam accession no. 
PF02811). The orthologous gene in S. pneumoniae (64% aa sequence identity) is 
described to be a phosphatase, and two amino acids in particular are reported to be 
important for phosphatase activity (Hagelueken et al., 2009). These two amino 
acids are among the conserved residues found also in CpsB (R139 and R206).  
 CpsC is predicted to be a membrane protein with intracellular N- and C-
termini. Two transmembrane helices are predicted after 25 aa from the beginning 
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of the protein and 33 aa before its end. The major central portion of the protein is 
extracellular and a Wzz superfamily domain (Pfam accession no. PF02706) is 
identified in this region. This domain is found in a number of related proteins 
involved in the synthesis of lipopolysaccharide, O-antigen polysaccharide, capsule 
polysaccharide and exopolysaccharides.  
 Finally, CpsD is predicted to be found in the cytoplasm, and possesses an 
AAA (ATPases Associated with diverse cellular Activities) domain (Pfam 
accession no. PF13614). CpsD is potentially a kinase, also by virtue of 
comparison with the orthologous genes CapB (40% aa sequence identity) in S. 
aureus (Olivares-Illana et al., 2008) and Wzd (59% aa sequence identity) in S. 
pneumoniae (Henriques et al., 2011). The conserved catalytic lysine residue 
described in the homologous proteins was identified also in CpsD(K49). 
Moreover we identified a repeated motif YGX in the C-terminal tail of CpsD, 
potentially constituting a phosphoacceptor region (Morona et al., 2003). 
 
 
 
 
FIGURE 9. Predicted subcellular localization and membrane topology of CpsABCD. 
Cartoon representing the CpsABCD proteins based on the information obtained by 
analyzing the protein sequences with PSORTb and Octopus. 
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Generation of isogenic CpsABCD mutant strains in GBS 
 To investigate the function of cpsABCD, twelve isogenic mutant strains 
were obtained in the GBS 515 (serotype Ia) genetic background (Table 2). The 
knock-out (KO) mutants cpsA, cpsB, cpsC and cpsD contained in-frame 
deletions where a large part of the gene sequence was removed. Furthermore, we 
designed ad hoc functional mutant strains to investigate the role of specific 
domains and/or enzymatic activities of the proteins. Thus, the entire extracellular 
portion of CpsA, or the LytR domain only, were deleted, generating strains 
CpsA(Δext) and CpsA(ΔLytR). We generated the two mutant strains 
CpsB(R139A) and CpsB(R206A), containing alanine substitutions in those 
conserved aminoacids reported to be important for phosphatase activity 
(Hagelueken et al., 2009). Little is known about CpsC and its orthologues, 
although the predicted C-terminal intracellular tail was suggested to be essential 
for CpsD activity in S. aureus and S. pneumoniae (Soulat et al., 2006, Byrne et 
al., 2011). We created the mutant strains CpsC(ΔC-term) and CpsC(Δext) where 
the predicted intracellular tail (33 aa), and extracellular domain (101 aa) of CpsC 
were deleted. As for CpsD, the putative kinase, the conserved catalytic residue 
Lys49 was mutated into alanine, generating strain CpsD(K49A). In parallel, the 
repeated motif YGX in the C-terminal tail of CpsD was truncated (12 aa), 
generating strain CpsD(ΔP-Tyr). All the mutants were viable and none of them 
showed significant growth defects as observed from their growth kinetics (Fig. 
10).   
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TABLE 2. GBS strains used in this work  
Strain name Description Mutated protein [full length aa] 
GBS 515 Wild type strain  - 
ΔcpsE cpsE deletion  Details in (Cieslewicz et al., 2001)  
ΔcpsA cpsA deletion Deletion of aa 11-452 [458] 
CpsA(Δext) Deletion of the CpsA extracellular 
domain 
Deletion of aa 96-458 [458] 
CpsA(ΔLytR) Deletion of the CpsA LytR domain Deletion of aa 236-458 [458] 
ΔcpsB cpsB deletion Deletion of aa 4-240 [243] 
CpsB(R139A) Point mutation in the phosphatase 
active site 
Arginine to alanine in position 139 
[243] 
CpsB(R206A) Point mutation in the phosphatase 
active site 
Arginine to alanine in position 206 
[243] 
ΔcpsC cpsC deletion Deletion of aa 1-222 [230] 
CpsC(ΔC-term) Deletion of the CpsC intracellular 
C-terminal portion 
Deletion of aa 198-230 [230] 
CpsC(Δext) Deletion of the CpsC extracellular 
domain 
Deletion of aa 53-153 [230] 
ΔcpsD cpsD deletion Deletion of aa 11-225 [232] 
CpsD(K49A) Point mutation in the autokinase 
active site 
Lysine to alanine in position 49 
[232]  
CpsD(ΔP-Tyr) Phosphoacceptor site C-terminal 
deletion 
Deletion of aa 213-224 [232] 
 
 
 
FIGURE 10. Growth curves of the wild type and mutant strains. Optical density 
(nm=600) of the wild type strain 515 and of the cps mutant strains in THB medium was 
monitored for 400 min. Growth curves are the mean of five different biological replicates. 
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Analysis of the cps operon transcription in CpsABCD mutant strains  
 CpsA has previously been reported to be involved in cps operon 
transcription (Cieslewicz et al., 2001, Hanson et al., 2012). We used qRT-PCR to 
analyze the transcription of the operon in all the mutant strains. Bacteria were 
harvested in logarithmic and early stationary phase and the transcription was 
measured using primers annealing to cpsA (with the exception of CpsA mutants, 
where we used primers annealing to cpsD) (Fig. 11). Compared to the wild type 
strain 515, mutant strains showed no prominent differences in relative expression 
of the cps operon, suggesting that none of the cpsABCD genes is involved in 
transcriptional regulation of the cps operon in the conditions tested. We also noted 
that the transcription of the cps operon was reduced in early stationary phase 
compared to exponential phase of growth.  
  
 
FIGURE 11. Quantification of the cps operon transcription. Cps operon transcription 
of the wt strain 515 and of its derivative cps mutant strains was measured by qRT-PCR 
using primers annealing to cpsA/D (black bars) and to cpsE (grey bars). Bacteria were 
harvested in logarithmic (Log) and early stationary phase (Stat). The relative fold 
expression for each strain was calculated in comparison with the wt strain 515 in log 
phase. Columns represent means of three independent experiments performed with 
triplicate samples. Error bars represent standard deviation. 
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The cps operon transcription was also quantified using primers annealing to cpsE, 
the first gene downstream cpsABCD. For all the strains, transcription measured 
with these primers was reduced in comparison to the transcript quantified on 
cpsA. This effect suggests possible RNA degradation of the long transcript 
starting from the 3’ end. Primers annealing to the last gene of the operon (neuA) 
were tested on the wild type strain and gave a signal even lower than the one 
measured with primers on cpsE thus confirming this hypothesis (data not shown). 
Using primers annealing to cpsE we could also exclude the presence of polar 
effects on the transcription of the cps operon due to the mutations introduced (Fig. 
11). 
 
 
CpsBCD forms an interdependent kinase/phosphatase system  
 The presence of CpsABD in the wild type and mutant strains was verified 
by Western Blot on total protein extracts (Fig. 12). In all cpsA mutants anti-sera 
failed to detect the presence of CpsA, possibly because antibodies are binding to 
the LytR domain of the protein which is not present in any of these strains. All the 
other mutants produced an amount of CpsA comparable to the wild type. CpsB 
and CpsD are present in all the protein extracts with minor expression differences, 
with exception for the respective knockout mutant strains. A reduced expression is 
observed for CpsB in the CpsA(Δext) and CpsA(ΔLytR) strains, possibly because 
the 3’ end of the cpsA gene is absent in these strains and harbors the ribosome 
binding site (RBS) of cpsB.  
 In S. pneumoniae the orthologous CpsBCD have been shown to constitute 
a phosphoregulatory system. The autokinase CpsD phosphorylates its C-
terminally located tyrosines (Morona et al., 2003). CpsB is the cognate 
phosphatase and CpsC is a membrane protein required for CpsD autokinase 
activity (Byrne et al., 2011, Bender & Yother, 2001). We hypothesized that these 
proteins have similar functions in S. agalactiae. The presence of putative 
phosphoproteins in total bacterial extracts was examined using an α-P-Tyr mAb 
(Fig. 12). CpsD appeared phosphorylated in the wild type strain, albeit showing 
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only a faint band. The three cpsB mutants showed an increased level of 
phosphorylation of CpsD, consistent with absent/reduced phosphatase activity of 
CpsB, and confirming that the amino acids R139 and R206 are necessary for 
phosphatase activity. A slight increase in CpsD phosphorylation is observed also 
in the CpsA(Δext) and CpsA(ΔLytR) strains, consistent with the reduced 
translation of the CpsB protein (see above). All the mutations in CpsD resulted in 
undetectable phosphorylation of this protein. We conclude that CpsD is an 
autokinase and when non-functional, it cannot be phosphorylated by other 
bacterial kinases. Moreover, we showed that one or more of the four tyrosines at 
the C-terminal of CpsD constitute the phosphoacceptor site, and that the lysine in 
position 49 is necessary for autokinase activity. In addition, if CpsC is absent or 
lacks the C-terminal intracellular tail, then CpsD is not phosphorylated. While, if 
only the extracellular portion of the protein is deleted, autophosphorylation 
activity of CpsD is preserved. Thus, the CpsC intracellular 33 aa tail is necessary 
for CpsD phosphorylation while the CpsC extracellular domain is dispensable. 
 
 
 
FIGURE 12. CpsABD proteins in wt and mutant strains. Western blots showing CpsA 
(-CpsA), CpsB (-CpsB), CpsD (-CpsD), tyrosine phosphorylation of CpsD (-P-Tyr 
mAb) and the loading control RNA polymerase subunit (-RNApol mAb in total 
protein extracts from 515 wt and the cps mutant strains. 
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Aberrant CPS production and localization in CpsABCD mutant strains 
 CPS production in wt and cps mutant strains was verified by flow 
cytometry using an α-CPSIa mAb. All the mutant strains exhibited a clear shift in 
mean fluorescence compared to the negative control (Fig. 13A), confirming that 
the strains produce a CPS possessing epitopes recognized by the monoclonal 
antibodies raised against the wild type CPS. The amount of CPS present on the 
surface of the different strains was quantified in bacterial extracts obtained by 
alkaline treatment (Wessels et al., 1990). We detected lower amounts of surface-
associated CPS in all the KO mutant strains compared to the wild type (Fig. 13B), 
consistent with previously published data (Cieslewicz et al., 2001). Most of the 
functional mutants also showed a significant capsule reduction, with the exception 
of mutants with point mutations in CpsB (CpsB(R139A) and CpsB(R206A)) and 
the CpsD(ΔP-Tyr) strain which lacks the putative tyrosine phosphoacceptor tail 
(Fig. 13B).  
 In S. agalactiae the CPS is covalently attached to the cell wall 
peptidoglycan (Deng et al., 2000). Certain mutant strains had little CPS attached 
to the bacterial cell surface (Fig. 13B) despite having normal cps operon 
transcription. We hypothesized that some of the CPS produced may be shed. To 
examine this possibility, serial dilutions of spent growth media were spotted on a 
nitrocellulose membrane and probed with an α-CPSIa mAb. All the cpsA mutants 
showed an increased amount of CPS in the medium compared to the wt (Fig. 
14A). The same phenotype was observed for the mutant strain with impaired 
autokinase activity (CpsD(K49A)) but not for the other cpsD mutants. The 
mutants ΔcpsB, ΔcpsC and CpsC(Δext) showed no detectable CPS in the culture 
supernatant, comparable to the negative control ΔcpsE which does not produce 
any CPS whatsoever. The ΔcpsA and CpsD(K49A) strains were chromosomally 
complemented and the amount of CPS released in the media by the complemented 
strains was restored to wild type levels (Fig. 14B). The mutant strains with 
increased CPS in the medium concomitantly showed a significant reduction in the 
amount of CPS attached to the bacterial surface (Fig. 13B), suggesting a defective 
attachment of CPS to the cell wall. These data suggest that CpsA could be the 
enzyme responsible for attachment of CPS to the cell wall, and that CpsD 
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autokinase activity is required. Specifically, the LytR domain of CpsA seems to 
be necessary for CPS attachment to the surface, since CPS is shed when this 
domain is removed.  
 
 
 
 
FIGURE 13. CPS production in the cps mutant strains. A, WT and cps mutant strains 
were incubated with a primary α-CPSIa mAb followed by a secondary goat α-mouse 
antibody conjugated to allophycocyanin (APC), and analyzed by flow cytometry. The 
unencapsulated ΔcpsE strain was included as a negative control. B, CPS from bacterial 
pellets was measured by a resorcinol assay. Columns represent means of three 
independent experiments performed with triplicate samples. Error bars represent standard 
deviation.  
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FIGURE 14. Aberrant CPS localization in mutant strains. Dot blots showing serial 
dilutions (1:2) of spent growth media spotted on a nitrocellulose membrane and probed 
with an α-CPSIa mAb. A, dot blot on the wild type and on all the cps mutants. B, dot blot 
on selected mutant strains and on their respective complemented strains.  
 
 
CPS length anomalies are observed in selected mutant strains  
 CPS from bacteria was extracted by mutanolysin treatment, separated on a 
polyacrylamide gel and examined by immunoblot with an α-CPSIa mAb (Fig. 
15A). Aberrant CPS length was observed in some mutant strains when compared 
to CPS extracted from the wt. We observed that strains where CpsD is absent/non-
functional (the three cpsD mutant strains and the CpsC(ΔC-term) mutant) 
displayed CPS with an unusually high molecular weight. Interestingly, these 
mutant strains are those where phosphorylation of CpsD was absent, suggesting 
that phosphorylation of CpsD may influence CPS chain length. In contrast, a very 
short CPS was produced by the strains lacking the extracellular domain of CpsC. 
Surprisingly, we could not detect any CPS in samples from ΔcpsB mutant by 
Western blot, despite previously having confirmed CPS production by FACS 
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analysis and CPS quantification (Fig. 13AB). Mutant strains that exhibited 
aberrant CPS phenotypes (i.e. ΔcpsB and all the cpsC and cpsD mutant strains) 
were chromosomally complemented. CPS extracts were prepared and analyzed by 
Western blot (Fig. 15B) and all the complemented strains appeared 
indistinguishable from the wild type, confirming that the phenotypes observed are 
solely due to the specific mutations introduced.  
 Immunogold transmission electron microscopy was performed in an 
attempt to visualize the CPS at the bacterial surface (Fig. 16). Wild type bacteria 
were observed both as electron dense diplococci or chains of cocci. Gold beads 
linked to α-CPSIa were uniformly distributed in a thin layer peripheral to the 
bacterial surface. The negative control (ΔcpsE), devoid of CPS, had very few if 
any beads associated with the bacteria. In the CpsD(ΔP-tyr) mutant, beads formed 
a wider layer around the bacterial periphery with very few beads in close 
proximity to the bacteria. In addition, scattered beads were also observed at a 
large distance from the bacterial surface, suggesting a more extended CPS. The 
ΔcpsB mutant, in comparison, showed a bead distribution similar to the wt but 
with much fewer gold beads. This is consistent with results shown in Fig. 13B 
indicating a lower CPS amount in this mutant.  
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FIGURE 15. CPS length differences in the wt and cps mutant strains. A, Western blot 
of CPS bacterial surface extracts from the wt and all the cps mutant strains. Lanes were 
exposed for different times, in order to permit visualization of CPS from all strains. B, 
Western blot of CPS bacterial surface extracts from the wt strain and from 
chromosomally complemented strains. CPS was detected with an α-CPSIa mAb. A 
protein molecular weight marker is included for approximate comparison. 
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FIGURE 16. Immunogold TEM on whole bacteria using an α-CPSIa mAb as primary 
antibody, and a secondary gold-beads conjugated antibody. Bacterial strains are indicated. 
 
 
Biochemical characterization of the CPS in selected mutant strains 
 On the basis of the Western Blot data, we selected a panel of strains 
exhibiting different CPS properties for further analytical characterization of the 
capsular polysaccharides. The ΔcpsA and CpsD(K49A) strains were selected 
because they partially release the CPS in the growth medium. CpsC(Δext) was 
chosen because it produces a very short polysaccharide. One liter cultures were 
used to obtain bacterial pellets that underwent alkaline treatment, and the CPS 
was subsequently purified by ethanol precipitation and diafiltration. A simplified 
procedure was set up to purify the CPS from the growth media. The NMR 
analysis confirmed the saccharide structural identity of purified CPS obtained 
from wild type and mutant strains, irrespective of whether they were derived from 
media or bacteria (Fig. 17).  
 In the ΔcpsA and CpsD(K49A) strains, the amount of CPS collected from 
the media represented the majority of the total CPS produced (70% and 77%, 
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respectively). In comparison, very little CPS was purified from the medium of the 
wild type strain 515. The relative molecular weight distribution of purified CPS 
was determined by HPLC using a pullulan reference standard to build a 
calibration curve. The average chain length of the CPS purified from the media of 
the two mutant strains was significantly higher than the CPS of the wild type 
strain (Tab. 3, Fig. 18). The ΔcpsA mutant released a CPS approximately 5 to 10 
times longer than the wild type. Interestingly, the CPS purified from the bacterial 
surface of ΔcpsA strain was instead comparable to that of the wild type. 
Using the CpsD(K49A) mutant we observed that the purified CPS from both 
fractions exhibit an extremely high molecular weight distribution (more than 10 
times longer than the wt), to the point where further size estimation was 
impossible. 
 We also investigated the CPS purified from the bacterial surface of the 
mutant strain CpsC(Δext), which showed shorter surface CPS in the immunoblot 
experiments (Fig. 15A). The amount of CPS extracted from the bacterial pellet of 
this mutant was higher than in the other mutant strains, and the molecular weight 
distribution of the purified CPS determined by HPLC indicated a 6-fold smaller 
CPS compared to the wt (Tab. 3, Fig. 18). The growth medium of this strain was 
not analyzed since previous experiments suggested a minimal release of CPS (Fig. 
14A). In conclusion, if CpsA is disrupted the amount of shed CPS increases 
dramatically and that CPS is very long, while retained CPS is shorter than that of 
the wild type. Concomitantly, if CpsD is unable to autophosphorylate, then 
attached and released CPS are both longer than the wild type, and increased 
shedding is again observed. Finally, it is noteworthy that shed CPS purified from 
medium was consistently much longer than wt CPS from the bacterial surface. 
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FIGURE 17. Comparison of 1H NMR spectra obtained for CPS extracts purified 
from bacterial pellets and from spent growth media. 
 
 
 
TABLE 3. Biochemical characterization of the purified CPS from selected mutant 
strains. Quantification of the CPS purified from bacterial pellets and from spent growth 
media from 1 liter cultures. The mean size of the CPS was estimated by HPLC-SEC. The 
size range represents 95% of the area of the molecular size distribution. 
 
Strain Fraction CPS (mg) Size (kDa) Range (kDa) 
515 Bacteria 4.1 167 49 - 616 
 
Medium 0.5 NA NA 
ΔcpsA Bacteria 2.8 237 62 - 1075 
 
Medium 6.7 >1330 115 - >1330 
CpsC(Δext) Bacteria 3.3 55 23 - 136 
CpsD(K49A) Bacteria 1.7 >1330 1013 - >1330 
 
Medium 5.6 >1330 >1330 
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FIGURE 18. Molecular size analysis of CPS from selected strains. Profiles for CPS 
extracts purified from bacterial pellets (solid lines) and from spent growth media (dotted 
lines) analyzed by SEC-HPLC. The molecular size of the polysaccharide was calculated 
by comparison with a calibration curve generated using pullulan standards.  
 
 
CpsC interacts with CpsA and CpsD 
 As seen in Western Blot experiments (Fig. 15A), mutant strains lacking 
CpsC or the extracellular domain of CpsC produced a short CPS, suggesting that 
the extracellular part of CpsC is in some way assisting polymerization. We 
hypothesized that CpsC interferes with CpsA termination of CPS polymerization. 
This implied a possible interaction between CpsC and CpsA, which was 
investigated using a Bacterial Two Hybrid (BACTH) system (Karimova et al., 
1998) (see Experimental Procedures for details). We observed a CpsA self-
interaction, suggesting a possible oligomerization of CpsA. Interestingly, we also 
observed an association between heterologously expressed CpsC and CpsA (Fig. 
19A). Such a direct interaction has not been previously reported, and suggests that 
CpsC may be forming a transient or stable complex with CpsA, thereby 
modulating the attachment of CPS to the cell wall. 
 A protein-protein interaction between the two homologous protein Wzd 
(CpsC) and Wze (CpsD) in S. pneumoniae has previously been shown (Henriques 
et al., 2011). Having observed that CpsD autokinase activity required the presence 
of CpsC (Fig. 12) we investigated a putative interaction between CpsC and CpsD 
of GBS by BACTH system. Indeed, we observed that heterologously expressed 
CpsC and CpsD interacted (Fig. 19B). Interestingly, we observed that this 
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interaction was abrogated when the CpsC C-terminal 33 aa tail was removed, 
suggesting that the tail directly interacts with CpsD. 
 
 
 
FIGURE 19. Analysis of protein interactions between CpsACD using a bacterial two 
hybrid system. A, Bacterial two hybrid (BACTH) analysis of CpsA and CpsD. T25-
CpsA was tested for interaction with T18-CpsA and T18-CpsC. B. BACTH analysis of 
CpsC and CpsD. T25-CpsD was tested for interaction with T18-CpsC and T18-CpsC(ΔC-
Term). Empty plasmids were tested together with fusion proteins as negative controls. 
The positive control used was the leucine zipper GCN4 fused to the T25 and T18 
fragments (Karimova et al., 1998). The formation of blue colonies indicates a protein–
protein interaction. Experiments were performed in triplicates and the same results were 
obtained for each replicate. 
 
 
CPS defects in mutant strains are associated with reduced adhesion to plates 
 The wild type strain 515 is a known biofilm-forming strain (Rinaudo et al., 
2010). The crystal violet assay on polystyrene plates is an initial screening for the 
adhesive properties of bacteria (O'Toole et al., 2000). We used this assay to 
investigate whether the different CPS phenotypes observed in the cps mutants 
may have an impact on the biofilm properties of GBS. GBS 515 wt gave a 
positive signal in the crystal violet assay (Fig. 20). In comparison, the 
unencapsulated isogenic mutant cpsE showed a weak signal. Similar phenotypes 
have already been observed and suggest that the presence of the CPS is required 
for bacterial aggregation and adhesion to plates (Xia et al., 2014). Such adhesion 
does not seem to directly correlate with CPS amounts, in fact strains producing as 
much CPS as the wt strain (i.e. the functional CpsB mutants and the CpsD(ΔP-tyr) 
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strain) (Fig. 13B) present opposite adhesion phenotypes (Fig. 20). All the strains 
showing reduced adhesion to plate possess very long attached polysaccharides 
(CpsC(ΔC-term) and all the cpsD mutants) (Fig. 15A) or shed the CPS in the 
growth medium (CpsD(K49A) and the cpsA mutants) (Fig. 14A). In conclusions 
our data suggest that strains with reduced CPS amounts or shorter CPS length are 
able to adhere to plates. On the contrary, absence of CPS, increase in CPS length 
and shed CPS are negative factors for biofilm formation.  
 
 
FIGURE 20. Biofilm formation assay on polystyrene plates. Adhesion to 96-well 
polysturene plate is measured by crystal violet assay for GBS 515 and all the cps mutant 
strains after growth in THB supplemented with 1% glucose for 18 hours. Solubilized 
crystal violet is quantified measuring the absorbance at 540 nm and is used as measure of 
the number of bacteria adhering to the well. Columns represent means of five replicates. 
Error bars represent standard deviation. Results were analyzed by one-way ANOVA 
comparing the mean of each column to the mean of the wild type strain 515. ns, not 
significant; ***, p<0.001.  
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GBS strains with CPS defects have different adhesion/invasion properties 
 During the initial stages of the infection GBS needs to attach to and invade 
epithelial cells. Alveolar epithelia are described as an entry site in early-onset 
disease. We tried to test whether aberrant CPS length, localization and amount 
may have an impact on the ability of GBS to associate with epithelial cells. An in 
vitro adhesion-invasion assay was used to test interactions between selected cps 
mutant strains and the lung epithelial cell line A549. 
 By comparing the wild type and the unencapsulated strain ΔcpsE we 
observed that GBS required the presence of the CPS to associate with cells (Fig. 
21A). In contrast, the presence of the CPS interfered with the invasion process 
(Fig. 21B) as previously observed (Hulse et al., 1993, Alkuwaity et al., 2012). 
Moreover, our results showed that strains producing very little CPS, such as the 
ΔcpsB and the ΔcpsD mutants (Fig. 13B), are less prone to associate with 
pulmonary cells, but are more capable invaders (Fig. 21AB). The same phenotypes 
were observed for the CpsC(Δext) mutant which produces a short capsule. In 
contrast, strains presenting little CPS attached to the bacterial surface, but 
increased shed CPS (the ΔcpsA and the CpsD(K49A) mutants) were both 
defective in the process of cell invasion. The same phenotype was observed also 
for the CpsD(ΔP-tyr) strain which produces an amount of CPS comparable to the 
wild type but with increased polymer length, and for the CpsC(Δext) mutant 
characterized by a short CPS (Fig. 21B). Furthermore, all the cpsD mutants which 
present long CPS on the bacterial surface, were deficient in the adhesion process 
(Fig. 21A). It is noteworthy that the invasion-adhesion properties of these strains 
are not correlated to the ability to adhere to the plates, as previously observed in 
the crystal violet biofilm assay (Fig. 20). This suggests that the phenotypes 
observed go beyond mere physicochemical properties of the bacterial surface (e.g. 
charge). Moreover, the reduced invasive capability of most of the strains is not 
dependent on the reduced association with cells. In conclusion, our results suggest 
that strains with reduced or increased CPS length are defective in adhesion to lung 
epithelial cells in vitro. In fact, the only mutant with phenotypes similar to the 
wild type was the ΔcpsA which produces an attached CPS with the same size of 
the wt. On the other hand, we observed that the unencapsulated strain and the 
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mutants producing very little CPS are more efficient in invading these cells 
irrespective of the CPS length.  
 
 
 
FIGURE 21. Association to the A549 lung epithelial cell line of the cps mutant 
strains. A, bacteria associated to the A549 lung epithelial cells after 2 h of infection. The 
number of bacteria is expressed relative to the total number of bacteria in the well after 
the infection. B, percentage of invasion was calculated as percentage of bacteria 
associated to the A549 cells which are found inside the cells. Each panel shows the mean 
values from three independent experiments each performed in triplicates. Error bars 
represent SEM. Results were analyzed by one-way ANOVA comparing the mean of each 
column to the mean of the wild type strain 515. ns, not significant; *, p<0.05; **, p<0.01; 
***, p<0.001.  
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DISCUSSION 
The cpsABCD genes are relatively well-conserved intra- and interspecies 
(Yamamoto et al., 1999, Cieslewicz et al., 2005). In this work we focused on 
these four conserved genes and their role in S. agalactiae CPS biosynthesis. 
Previous studies on homologous proteins from S. pneumoniae have provided 
molecular details on the phosphorylation and dephosphorylation involving CpsB, 
C, and D (Morona et al., 2000, Bender & Yother, 2001, Byrne et al., 2011), but 
the role of this phosphoregulatory system in the context of the CPS biosynthesis is 
not completely understood. Moreover, the notion that similar events may be 
occurring in S. agalactiae is merely an argument by analogy. We attempted 
mutational studies to experimentally elucidate the role of CpsABCD in S. 
agalactiae CPS biosynthesis, including mutations that could shed light on the 
potential interdependencies between these proteins. Our data suggest that CpsA, 
B, C and D proteins are not essential for the biosynthesis of the capsular 
polysaccharide repeating units, since all the mutant strains retained the ability to 
produce a CPS recognizable by monoclonal antibodies against the wild type CPS. 
However, we observed differences in CPS length and localization in our mutant 
strains, suggesting that these proteins are involved in controlling CPS elongation 
and attachment to the cell wall. Following is a step-by-step discussion of the 
working model we propose for CpsABCD (Fig. 22). 
In the final steps of CPS biosynthesis, the newly synthesized repeating unit 
(RU) anchored to a polyisoprenoid phosphate lipid is flipped to the outer side of 
the bacterial membrane, where CpsH is presumably responsible for the 
polymerization of the repeating units (Fig. 22A). By analogy with other Wzy-
dependent systems, such polymerization occurs bottom-up. The nascent CPS is 
removed from the lipid through a phosphotransferase reaction, and subsequently 
linked to a single membrane-anchored RU (Yother, 2011). The final product is a 
CPS that is removed from the membrane lipid and covalently attached to GlcNAc 
in the peptidoglycan backbone (CPS-PG) (Deng et al., 2000). This linkage 
effectively renders further polymerization impossible. Our results suggest that the 
LytR domain of CpsA is necessary for this activity. In fact, we observed that 
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when this domain was removed, mutants showed defects in CPS attachment to the 
bacterial surface and, as a corollary, increased amounts of CPS was shed into the 
growth medium. CpsA belongs to the LytR-CpsA-Psr (LCP) protein family, 
together with two paralogues, and it was suggested that these enzymes are 
involved in the final steps of cell wall assembly (Hubscher et al., 2008). A study 
of the homologous Cps2A protein in S. pneumoniae proposed that it may be 
responsible for transfer of CPS from the membrane lipid to the cell wall 
peptidoglycan (Kawai et al., 2011). However, the deletion of cps2A in S. 
pneumoniae was not sufficient to obtain a clear CPS release phenotype, possibly 
due to redundancy of LCP protein activities (Eberhardt et al., 2012). In 
comparison, we observed increased CPS release for all the cpsA mutant strains, 
even though attachment of CPS to the bacterial surface was not abolished 
completely. Thus, a possible redundancy between LCP proteins remains a 
possibility. It is noteworthy that we find no evidence for CpsA involvement in the 
transcriptional regulation of the cps operon, in contrast to previous literature 
(Cieslewicz et al., 2001, Hanson et al., 2012). 
We speculate that the CpsH polymerase and CpsA compete for the same 
substrate (the nascent CPS). While the enzymatic reaction involving CpsH results 
in elongation of the CPS by one RU at a time, the CpsA reaction instead 
terminates elongation by securing CPS to the cell wall. We suggest that the 
activity of CpsA is moderated by CpsC (Fig. 22B). This notion is supported by the 
direct interaction of CpsC and CpsA in a bacterial two-hybrid system (Fig. 19A). 
Moreover, deletion of the extracellular part of CpsC results in abnormally short 
CPS, suggesting a premature termination of CPS synthesis by CpsA (Fig. 18). 
An interaction between CpsC and CpsD was also observed, strictly 
dependent on the presence of the short 33 aa intracellular C-terminal tail of CpsC 
(Fig. 19B). Homologues of CpsC and CpsD in Gram-negative bacteria are found 
as a single multi-domain protein (Olivares-Illana et al., 2008, Whitfield & 
Paiment, 2003). Taken together, this suggests that CpsC and CpsD form a 
heterodimer or more complex multimers and act in concert. We show that CpsD is 
an autokinase and phosphorylates tyrosines in its C-terminus. In our model we 
propose that the phosphorylation state of CpsD directs the conformation of the 
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CpsC extracellular domain through interaction with the C-terminal tail (Fig. 22B). 
The notion of CpsCD acting in concert is supported by a model of the 
homologous proteins CapAB in S. aureus, suggesting an octamer complex with 
conformational changes induced in response to the phosphorylation state of CapB 
(Olivares-Illana et al., 2008). 
Among our mutant strains we observed both very long and very short 
CPS. We believe that these phenotypes are a result of CpsCD exerting control 
over the action of CpsA. I.e., a very short CPS suggests unchecked CpsA action, 
and premature termination of CPS biosynthesis. CpsCD can be considered to have 
entered a ‘permissive’ state, which coincides with CpsD being 
hyperphosphorylated. In contrast, when CpsD is absent or non-phosphorylated 
(CpsC(C-term) and all the cpsD mutants) long CPS are produced, implying that 
the termination of CPS biosynthesis is impeded. We also observed that when the 
CpsD protein is in full-length form but non-functional (CpsD(K49A) mutant) the 
CPS is not only longer than in the wild type, but it is also released into the 
medium. This phenotype is similar to those observed for the cpsA mutants, and 
further supports the notion that CpsD dephosphorylation is directly or indirectly 
inhibiting CpsA activity. Admittedly, the data on mutants cpsD, Cps(P-tyr) and 
CpsC(C-term) are not immediately consistent with this model, as the CPS is still 
attached to the bacterial surface despite having an increased size. However, these 
mutants all have in common structural truncations that may affect the integrity of 
the CpsCD complex, resulting in an anomalous configuration with unpredictable 
consequences. Theoretically possible alternatives to our model include a direct 
inhibition of polymerization by CpsA, or that CpsC facilitates the polymerization 
process. In our view, both possibilities are less consistent with the data presented 
here, compared to the model we propose. 
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FIGURE 22. Model of CpsABCD involvement in CPS biosynthesis. A, Topology and 
subcellular localization of the CpsABCD proteins and of the CpsH polymerase based on 
computer predictions and/or literature. Repeating unit (RU), the capsular polysaccharide 
(CPS) and the cell wall peptidoglycan (PG) are also represented in the panel. B, 
Schematic representation of the working model proposed for the CpsABCD proteins. 
Arrows represent enzymatic reactions, the bar-headed line is an inhibitory effect, and the 
dotted line represents interdependency. 
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A comparison between the phenotypes of mutant strains cpsA and 
CpsD(K49A) presents an interesting enigma. In both cases, a majority of the CPS 
is shed into the medium and is also unusually long. Prior to PG attachment by 
CpsA, the CPS is tethered to the membrane through the lipid moiety. If the CPS is 
not transferred from the lipid moiety to the PG, polymerization continues 
unhindered and results in CPS polymers that are 10-fold longer or more compared 
to the wild type size. We speculate that shedding occurs because the lipid moiety 
alone is insufficient to keep such a large molecule tethered in the membrane 
through hydrophobic interaction. In the cpsA strain only normal-sized CPS is 
found attached, while in the CpsD(K49A) mutant the attached CPS is as long as 
the shed CPS. A difference between the mutants is that the CpsD(K49A) has a 
fully functional CpsA, although the CpsCD is in a permanent ‘non-permissive’ 
state in relation to CpsA. On the other hand, in the case of the cpsA mutant, 
CpsCD undergoes normal phosphorylation cycling, and will thus periodically 
enter a ‘permissive’ state where the CPS is subjective to hydrolysis, and may 
become anchored to PG by other LCP proteins, as previously suggested for S. 
pneumoniae (Eberhardt et al., 2012). Presently, we do not have a clear 
understanding of how these mutations result in two somewhat different 
phenotypes. 
In summary, this work examines the concerted action of CpsABCD in the 
Gram-positive bacterium S. agalactiae. Through the use of multiple functional 
and structural mutations, the resulting phenotypes allowed us to approach the 
proteins as a system, and define interdependencies. CpsABCD sit at the finishing 
line of CPS biosynthesis, and the cyclic phosphorylation of CpsD is a main switch 
that ensures secure attachment to the cell wall, indirectly determining the average 
length of CPS. A steady-state is obtained through autophosphorylation of CpsD 
and dephosphorylation by CpsB. Perturbances in this system lead to distinct 
anomalies in capsular localization and polymer length. Apparently, the bacteria 
are employing a sweet spot in the CpsABCD system, where the current 
equilibrium results in CPS of a ‘suitable’ length and that is securely anchored to 
the cell surface.  
The reason why GBS produces a CPS of a particular design represents a 
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fascinating subject. In an attempt to understand the biological consequences of 
CPS deviations, we performed in vitro biofilm and cell infection assays. By 
comparing the wild type and the cpsE mutant, we observed that the 
unencapsulated strain is less efficiently adhering both to polystyrene plates and to 
the A549 pulmonary cells layer. In contrast, the mutant strain showed an 
increased percentage of invading bacteria in comparison with the wild type. These 
results suggest that invasion is attenuated by the CPS and that on the other hand 
the CPS is necessary to promote association to cells. Inhibition of cell invasion by 
the CPS has already been reported using GBS and different cell types (Gibson et 
al., 1995, Hulse et al., 1993). However, our results are partially in contrast with 
previously published data showing that strains devoid of CPS were more efficient 
both in cells adhesion and invasion (Soriani et al., 2006). With regard to the in 
vitro biofilm assay, our findings are similar to those reported by Xia and 
coworkers (Xia et al., 2014).  
To our knowledge the impact of the differences in CPS amount and length 
on the adhesion-invasion process has not been investigated in GBS or other 
related bacteria. To this aim, we selected a panel of mutant strains with different 
capsule phenotypes and we analyzed them using the assays described. We 
observed that increased CPS lengths caused defects in adhesion both to 
polystyrene plates and to the A549 pulmonary cells layer. These findings suggest 
that long CPS may mask specific components important for adherence or may 
nonspecifically attenuate this process by steric hindrance or surface charge 
(Absolom, 1988). Interestingly, also the strains that were completely devoid of 
CPS or producing very little CPS were poorly associated to cells, thus suggesting 
that the presence of the polysaccharide is a prerequisite for adhesion to this cell 
line. From the invasion assay we observed that the unencapsulated strain and the 
mutants producing very little CPS were more efficient in invading cells 
irrespective of the CPS length. This result confirms the theory proposed for 
different encapsulated bacteria that the CPS attenuate the invasion process 
(Soriani et al., 2006, Malin & Paoletti, 2001). In strains that were shedding the 
CPS, we observed that the presence of the CPS in the medium does not have an 
apparent impact on GBS association to A549 cells. Analyzing strains with very 
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little but long CPS attached to the bacterial surface (the cpsD and the 
CpsD(K49A) mutants) we saw that the strain releasing the CPS in the medium 
was significantly less efficient in cell invasion compared to the other strain. 
Experiments showed that preincubation of the cell monolayer with purified 
capsule is not inhibiting the invasion of the cells by GBS (Hulse et al., 1993) so 
the reduced invasion that we observed could be an effect of the reduced 
association.  
In conclusion our results showed that strains with CPS length different 
from the wild type were defective in associations to lung epithelial cells in vitro. 
Moreover, we observed that the unencapsulated strain and the mutants producing 
very little CPS were more efficient in invading these cells, irrespective of the CPS 
length. However, strains without CPS are known to be more susceptible to killing 
by human neutrophils and less virulent (Wessels et al., 1989, Marques et al., 
1992). These findings suggest two possible scenarios, the first is that during 
evolution GBS may have found an equilibrium resulting in a CPS with specific 
features that ensure the best trade-off to adapt to the different environment 
encountered during pathogenesis. The second is that the length of the CPS or its 
amount may be regulated in response to external factors, i.e. reducing CPS 
production to promote intracellular invasion and increasing capsule expression to 
evade host defenses. A recent paper showed that the phosphatase activity of the 
CpsB homologue in S. pneumoniae increases with growth in high-oxygen 
conditions causing a reduction in the total amount of CPS produced (Geno et al., 
2014). Chemical compounds able to inhibit the activity of this protein have been 
described and were shown to reduce CPS production in S. pneumoniae (Standish 
et al., 2012). However, taken together, these two works underline that there is not 
a clear correlation between the activity of the CpsB phosphatase and the amount 
of CPS produced by S. pneumoniae. 
The CPS of GBS and of other bacteria represents an important virulence 
factor involved in several aspects of bacterial pathogenesis. With this work we 
have shed light on the mechanism used by GBS to ensure the attachment of the 
CPS to the cell wall and to indirectly determine the length of this molecule. We 
also observed that differences is CPS size, amount and localization are correlated 
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to different adhesion-invasion properties. However, the understanding of whether 
CPS in GBS and other bacteria adapts to the external environment remains a 
fascinating subject for future studies. We believe that a detailed comprehension of 
the CPS biosynthesis pathway would not only be scientifically exciting, but would 
also permit to identify target mechanisms for drug design and biotechnological 
applications.   
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